Track market-moving stories before they get noisy

UNIVEST FINANCIAL Corp boosted its position in shares of NVIDIA Corporation (NASDAQ:NVDA – Free Report) by 4.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 330,307 shares of the computer hardware maker’s stock after acquiring an additional 14,092 shares during the quarter. NVIDIA accounts for approximately 3.2% of UNIVEST FINANCIAL Corp’s investment portfolio, making the stock its 8th biggest holding. UNIVEST FINANCIAL Corp’s holdings in NVIDIA were worth $66,091,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVDA. J. Stern & Co. LLP increased its position in NVIDIA by 13,709.1% during the fourth quarter. J. Stern & Co. LLP now owns 125,760,307 shares of the computer hardware maker’s stock worth $23,454,297,000 after buying an additional 124,849,603 shares during the last quarter. Amundi boosted its stake in shares of NVIDIA by 10.4% during the 1st quarter. Amundi now owns 133,768,018 shares of the computer hardware maker’s stock worth $23,329,141,000 after acquiring an additional 12,575,177 shares during the period. SEB Asset Management AB bought a new position in shares of NVIDIA during the 1st quarter worth approximately $1,692,807,000. Employees Provident Fund Board acquired a new position in shares of NVIDIA during the 4th quarter worth approximately $1,243,336,000. Finally, H&H International Investment LLC raised its stake in NVIDIA by 91.3% in the 1st quarter. H&H International Investment LLC now owns 13,843,775 shares of the computer hardware maker’s stock valued at $2,414,354,000 after acquiring an additional 6,606,675 shares during the period. Institutional investors own 65.27% of the company’s stock.

Key Stories Impacting NVIDIA Here are the key news stories impacting NVIDIA this week:

Positive Sentiment: NVIDIA authorized an additional $150 billion for share repurchases, raising total remaining authorization to approximately $235 billion through fiscal 2028. The move signals management’s confidence in the company’s cash generation and suggests it views the stock as attractively valued. Stock Market Today, Sept. 30: Nvidia Authorizes $150B Buyback, Lifting Total to $235B Positive Sentiment: The latest bullish case centers on sustained AI spending. NVIDIA’s data-center revenue reportedly surged 117% year over year to $89 billion, while management continues to forecast substantial growth despite the company’s enormous scale. Analysts cited valuation, hyperscaler capital expenditures and the company’s full-stack AI platform as potential upside drivers. Nvidia’s Demand Outlook Still Supports The Bull Case Positive Sentiment: Political and regulatory developments were also favorable. President Donald Trump reportedly supported industry self-regulation at a White House AI meeting attended by CEO Jensen Huang, reducing near-term concerns that stricter rules could slow AI deployment. NVIDIA’s new AI safety platform could further support demand for inference, monitoring and networking infrastructure. Nvidia Was the Big Winner of Trump’s AI Lunch, Here’s Why Positive Sentiment: NVIDIA’s reported agreement to acquire Hugging Face for nearly $13 billion would expand its reach into open-source models, developer tools, datasets and AI distribution. The company is also investing in AI infrastructure partners, reinforcing its broader ecosystem strategy beyond GPUs. Nvidia just spent nearly $13 billion on something other than GPUs Neutral Sentiment: Softer-than-expected inflation helped support growth-oriented technology shares by reducing immediate expectations for additional Federal Reserve rate increases. However, higher interest rates remain a key valuation risk for AI-linked stocks. Why is Nvidia stock rising on Wednesday? Negative Sentiment: Risks remain around an AI spending slowdown, particularly if hyperscalers reduce capital expenditures. DeepSeek’s work with Huawei on software for alternative AI chips could also challenge NVIDIA’s software moat, while rising memory and networking costs may pressure gross margins. Investor Michael Burry’s reported bearish options position adds to skepticism, although it has not changed the company’s fundamental outlook. If AI Capex Cracks, Nvidia Could Feel It Before Meta Does Insider Buying and Selling In other news, CFO Colette Kress sold 34,918 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $219.05, for a total transaction of $7,648,787.90. Following the completion of the sale, the chief financial officer directly owned 765,103 shares in the company, valued at approximately $167,595,812.15. This represents a 4.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Timothy S. Teter sold 30,460 shares of the firm’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $222.80, for a total value of $6,786,488.00. Following the completion of the transaction, the executive vice president owned 2,687,660 shares in the company, valued at $598,810,648. The trade was a 1.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,766,118 shares of company stock valued at $399,450,353 over the last 90 days. 3.94% of the stock is owned by corporate insiders. NVIDIA Trading Up 0.5% NVDA stock opened at $228.38 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.85 and a current ratio of 4.59. The company’s 50-day simple moving average is $217.76 and its 200 day simple moving average is $206.94. NVIDIA Corporation has a 52 week low of $164.27 and a 52 week high of $236.54. The company has a market capitalization of $5.50 trillion, a PE ratio of 28.87, a price-to-earnings-growth ratio of 1.76 and a beta of 2.22.

NVIDIA (NASDAQ:NVDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 26th. The computer hardware maker reported $2.22 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.13. NVIDIA had a net margin of 63.66% and a return on equity of 96.04%. The business had revenue of $96.22 billion during the quarter, compared to analysts’ expectations of $92.27 billion. During the same quarter in the previous year, the company earned $1.05 EPS. The business’s revenue was up 105.9% on a year-over-year basis. As a group, sell-side analysts anticipate that NVIDIA Corporation will post 9.25 earnings per share for the current year.

NVIDIA declared that its Board of Directors has approved a stock repurchase plan on Monday, September 28th that permits the company to repurchase $150.00 billion in shares. This repurchase authorization permits the computer hardware maker to purchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

NVIDIA Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Thursday, September 10th will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Thursday, September 10th. NVIDIA’s payout ratio is 12.64%.

Wall Street Analyst Weigh In NVDA has been the subject of several research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of NVIDIA in a report on Monday, August 31st. Weiss Ratings restated a “buy (b)” rating on shares of NVIDIA in a research note on Wednesday, July 8th. Stifel Nicolaus set a $315.00 target price on shares of NVIDIA in a report on Thursday, August 27th. Mizuho set a $315.00 price target on shares of NVIDIA and gave the company an “outperform” rating in a research note on Thursday, August 27th. Finally, DZ Bank restated a “buy” rating on shares of NVIDIA in a research report on Wednesday, August 26th. Four research analysts have rated the stock with a Strong Buy rating, fifty have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $324.14.

Check Out Our Latest Report on NVDA

NVIDIA Profile (Free Report)

NVIDIA Corporation is a technology company that designs accelerated computing platforms, graphics processing units (GPUs), central processing units (CPUs), networking products and related software. Its technologies are used in artificial intelligence, data centers, scientific and technical computing, gaming, professional visualization, automotive systems and robotics.

The company’s products include GeForce GPUs and gaming software, data center computing platforms, networking solutions, and enterprise software for AI development and deployment.

Featured Articles Five stocks we like better than NVIDIA Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors? O’Reilly Automotive’s Stock Slump Hides a Stronger Business McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test

Receive News & Ratings for NVIDIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NVIDIA and related companies with MarketBeat.com's FREE daily email newsletter.

Nvidia just unlocked nearly $100 billion in buyback firepower while demand for its chips outstrips supply through 2028, and the valuation tells a story most investors are reading backwards.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) just expanded its capital return program, adding another data point to its long-term investment case.

My thesis is simple. Every AI lab, cloud provider, and government needs the machinery NVIDIA makes, and it can’t build enough of it. Management said on the August call that “NVIDIA Compute is fully utilized across every cloud we serve,” and it expects supply to remain a bottleneck at least through the end of fiscal year 2028. A business sold out for years carries unusual revenue visibility.

Buyback Firepower Signals Management Confidence The board added $80.0 billion to the repurchase authorization in May 2026, leaving about $99.0 billion available at the end of Q2 FY2027. That quarter, NVIDIA returned a record $26 billion: $20 billion in buybacks and $6 billion in dividends. Against a plan to return 50% or more of free cash flow, it returned 60% year to date, and management said it intends to “increase and return excess free cash flow net of strategic uses.” The quarterly dividend also rose from $0.01 to $0.25 per share. Every share retired with internally generated cash gives remaining shareholders a bigger claim on future profits.

Three Numbers Driving NVIDIA’s Momentum Growth is accelerating. Q2 revenue hit $96.22 billion, up 105.85% year over year, the fourth consecutive quarter of accelerating growth. Guidance calls for $108.0 billion next quarter, with preliminary fiscal 2028 growth of about 70%.

Each generation makes more. Revenue per gigawatt rose from $18 billion for Hopper to $25 billion for Blackwell and $40 billion for Vera Rubin, now in full production.

The balance sheet is a strong. Debt to equity is at 0.0726, interest coverage at 503.4x, and return on invested capital near 92.2%. Q2 EPS of $2.22 topped the $2.09 consensus, the 5th consecutive beat.

How NVIDIA Stacks Up Against AMD and Broadcom Advanced Micro Devices (NASDAQ:AMD) trades near 40 times forward earnings versus NVIDIA’s 25, with a trailing operating margin of 17.2% against NVIDIA’s 66.2%. AMD carries a higher valuation alongside lower profitability.

Broadcom (NASDAQ:AVGO) looks cheaper at about 19 times forward earnings and yields 0.74%. Yet its return on equity of 44.3% trails NVIDIA’s 117.2%, and its latest quarterly revenue growth of 85.5% falls behind NVIDIA’s 105.9%. NVIDIA’s modest valuation premium comes with faster growth and higher returns.

Risk I Track Every Quarter Supply obligations reached $279.0 billion, mostly memory for Vera Rubin, and guarantee obligations for partners are capped at $108.5 billion. Days sales outstanding stretched to 60 days from 45. A pause in AI spending could make those commitments hurt, and the price to free cash flow of 57 leaves little margin.

Guidance already excludes China data center compute revenue. Balancing that risk, top-five hyperscaler capex is expected to reach nearly $800 billion in 2026 and $1.3 trillion in 2027. Somebody has to power, cool, and network all that spending. We rounded up seven suppliers riding the same wave in a free AI infrastructure report.

Catalysts Ahead of the November Report Vera Rubin should make up about 20% of data center revenue in Q3, and the next earnings report lands November 17. Keep an eye on whether Vera Rubin’s ramp and continued buybacks keep pace with management’s free cash flow return targets.

Contact [email protected] for any questions or corrections.

watch now

Walmart is aiming to make it as easy as possible for its customers to find exactly what they want.

The retailer is leveraging three new tools tied to its digital shelf labels for both customers and store associates to better find products. It's the latest part of the company's push to modernize its technology and incorporate artificial intelligence into its business.

"We are people-led, tech-powered," said Greg Cathey, Walmart's senior vice president of digital transformation. "But the way we look at it is AI as a way to help associates do their job and free up time to allow them to invest in what they love to do most, which is spend more time with customers and their fellow associates."

The new feature for shoppers, called Shop to Light, allows customers to find specific products on the Walmart app, navigate to the correct aisle in the store and then flash the digital shelf label of the product to locate it. The retailer is now incorporating it widely following a pilot program.

That tool is also paired with Pick to Light and Stock to Light, which use the same capabilities to help store associates pick items for digital orders and stock products. All three features will be rolled out to stores companywide by the holiday season, Cathey said.

"This is a use case that customers have asked us for, associates have asked us for," Cathey said. "It gives them time back, and I think if you look at a lot of what we're trying to do, it's all around convenience and being able to help associates and customers free up that time to invest it where they want."

The rollout comes as convenience and speed — particularly in the delivery and pickup segments — have become critical pieces of Walmart's efforts to increase sales. While Walmart's business has grown steadily, and its e-commerce sales continue to soar, investor concerns about its comparable sales and revenue outlook weighed on its stock after its most recent earnings report in August.

Walmart stores carry roughly 120,000 items. Cathey said it's a priority for the company to provide that large range of products while making it easier for customers to locate precise items.

While the company does not publicly share any financial aspects of the program, Cathey said the new features at pilot stores allow associates and customers to have more time while shopping and stocking. The Shop to Light feature has already seen 5 million flashes from customers since it began rolling out to limited locations this summer.

He said these new features will be especially important as the retailer heads into the busy holiday season, and the company views them as "a big win" for time savings.

Walmart began using digital shelf labels, as opposed to paper labels, to allow automatic and systemwide price changes to be rolled out at once. The company currently has more than 4,300 stores with digital shelf labels, and expects them to be installed across the chain by the end of the year, according to Walmart.

He added that the label prices are changed overnight, when customers aren't in the store, and the system has human oversight as well to ensure it has "robust governance" and doesn't make mistakes. Currently, roughly 90% of the sections within the store have digital shelf labels, he said.

"We don't look at it as technology for technology's sake," Cathey said. "So we always have a human in the loop, and we're very focused on human judgment and their ability to make decisions."

A broader technology pushWalmart has been investing in its technology to modernize the business on both the consumer-facing side and in internal operations.

It's rolled out an AI agent to help customers with shopping, automated its supply chain, invested in radio frequency identification tags and set the stage for agentic commerce as it embraces AI. It's also spent billions on modernizing its store locations.

On Walmart's most recent earnings call, its CEO, John Furner, said the company is seeing significant returns on its technology strategies, including its investments in AI.

"We believe AI will improve nearly every part of our business by making shopping better, and our associates' work easier," he said.

Still, digital shelf labels and the company's AI push have sparked backlash. They have raised concerns about dynamic pricing and fears that digital labels could lead to price surges or privacy issues with collecting shopping data from customers.

But in an open letter last week, Furner said the company is continuing to "price the product, not the person," adding the retailer does not plan to use customer information to set prices.

"Your income, shopping history, urgency or what we think you could pay won't change the price," Furner wrote.

Cathey, who's been in his position for nearly a year, said his biggest priority when taking over the role was to focus on accelerating the speed of the technology that Walmart uses while keeping human oversight.

Several state legislatures, including New Jersey, have passed measures to restrict digital shelf labels over pricing concerns. Walmart said it has the feature in all of its stores in New Jersey.

Walmart in a statement called the policy an "overreaction, as digital shelf labels are not a tool for surveillance pricing and are simply a modern way to display prices."

Walmart has also invested in drone delivery – which has come under similar scrutiny over privacy concerns – to deliver products to customers in as fast as 30 minutes. That delivery option is available in select states, including Texas and Florida.

Ultimately, Cathey said the new digital shelf label features are all part of the company's bigger goal to ensure that store associates have more time to help meet the individual needs of customers.

And while investors debate whether physical retail or e-commerce is more important to the company's business, Cathey said the new features show that both go hand in hand.

"It's not one or the other anymore. It's both," he said. "We don't look at it as a store or an e-commerce fulfillment. They're actually one and the same."

Citi, Barclays, and Wells Fargo all lifted their HPE price targets after Networking Investor Day, yet the three firms land in very different places on whether the stock's explosive run has already consumed the upside.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Three Wall Street firms raised their price targets on Hewlett Packard Enterprise (NYSE:HPE | HPE Price Prediction) after its Networking Investor Day.

Citi moved its target to $92 from $76, Barclays to $83 from $79, and Wells Fargo to $63 from $54. None of the three changed its rating.

All three point to networking as HPE’s main growth engine, but they still disagree on how much of that upside the stock already prices in.

Ticker Company Firm Action Old Rating New Rating Old Target New Target HPE Hewlett Packard Enterprise Citi Price Target Raised Buy Buy $76 $92 HPE Hewlett Packard Enterprise Barclays Price Target Raised Overweight Overweight $79 $83 HPE Hewlett Packard Enterprise Wells Fargo Price Target Raised Equal Weight Equal Weight $54 $63 Analysts Agree Networking Now Drives the Story Barclays said HPE raised its fiscal 2027 networking outlook to high-teens to low-20s percent growth. At its September earnings call, the company had guided to 14% to 17%, and that figure left out the Helios platform from Advanced Micro Devices (NASDAQ:AMD). Barclays now says HPE sees Helios as an over $1B networking opportunity over the next two years.

Citi said the near-term financial update surprised investors and showed “strong” confidence in sustained growth over the longer term. The firm called the company’s messaging “incrementally bullish” for the shares.

Wells Fargo, taking a more measured view, cited a positive strategy overview and a higher FY27 outlook, and it found the Juniper integration better than expected. It added that performance on winning market share will be the focus.

HPE Snapshot: A Record Quarter Set the Stage Third-quarter fiscal 2026 revenue reached $12.21B, up 32.7% from a year earlier. Non-GAAP EPS of $1.11 beat the $0.93 consensus, making it the fifth straight quarterly EPS beat. Networking revenue rose 74.9% to $2.89B, and routing climbed 270%.

Orders for HPE’s networks for AI hit a quarterly record of $700 million. Juniper synergies remain on track for $600 million in annual run-rate savings by the end of FY28.

Why These Target Hikes Matter Now Hewlett Packard Enterprise stock trades at $63.71. That is up 168.23% year to date and 22.24% over the past month. The price already sits just above Wells Fargo’s new target, which helps explain why that firm still rates the shares Equal Weight.

Earnings estimates are rising along with the price. Consensus FY27 EPS now stands at $4.5974, compared with $4.1063 30 days ago. Analysts made 15 up revisions in that period and zero down ones.

What It Means for Your Portfolio A stronger networking outlook supports HPE’s growth case for long-term investors, though the stock’s sharp run-up raises the bar for performance. Shortages of DDR5 memory and NAND flash continued to restrict the conversion of demand into revenue. The company also lists trade policy and Juniper integration as risks.

All that AI-driven networking demand has to be powered and cooled by someone, and the suppliers behind the data-center expansion rarely get the attention the chipmakers do. We featured seven of them in a free report you can grab here.

Income-focused investors get a modest dividend yield of 0.94%. HPE also plans to return at least 75% of fourth-quarter free cash flow to shareholders.

The next checkpoint is the fiscal fourth-quarter report. HPE has guided for revenue of $13.9B to $14.8B and non-GAAP EPS of $1.20 to $1.30. Investors should also keep an eye on Helios ordering, which management expects to open later in the calendar year.

Contact [email protected] for any questions or corrections.

Hormel Foods has raised its dividend for 60 straight years, but something just happened on the earnings statement that has never happened before in two decades of records, and it raises a serious question about whether that streak has a…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Hormel Foods (NYSE:HRL | HRL Price Prediction) has raised its dividend for 60 consecutive years, a record that puts it on nearly every retiree’s short list. Its own guidance now tells a harder story: Hormel expects fiscal 2026 GAAP diluted EPS of $1.06 to $1.12, below its $1.17 annualized dividend. A high yield is only as good as the company’s ability to keep paying it, and that ability is under real strain.

Quick test: a dividend becomes unsustainable when earnings and free cash flow stop covering it and the company leans on cash reserves or debt to keep the checks going out.

Hormel Foods (HRL): A 5.9% Yield Built on a Falling Share Price At $19.97, Hormel yields 5.89%. For a low-volatility staple behind SPAM, Skippy, Planters and Jennie-O, with a beta of 0.315, that looks like a sleep-at-night income stream.

Look at where the yield came from. The quarterly dividend rose from $0.245 in 2021 to $0.2925 today, and the latest raise, from $0.29, was roughly 1%. Over the same stretch the shares fell 43.11% across five years, 15% over the past year and 7.42% in the past month alone. The yield expanded mainly because the price collapsed while dividend growth slowed to a crawl. This is a classic trap setup.

A Payout Line Hormel Had Not Crossed in Two Decades Hormel is an ordinary corporate, so earnings per share and net income are the proper metrics for coverage. In fiscal 2025, Hormel paid $633.2 million in dividends against net income of $477.8 million. In annual records going back to fiscal 2006, that was the first year dividends paid exceeded net income. Net income fell 40.6% that year.

Fiscal 2026 extends the problem. GAAP EPS guidance was cut to $1.06 to $1.12 from $1.28 to $1.37, and the original range was $1.29 to $1.39. Trailing diluted EPS is just $0.62. The damage traces to a $56M loss on the Brazil sale, a $48.2M impairment on an Indonesia stake and a $37.5M antitrust settlement.

Bulls will point to adjusted EPS guidance of $1.45 to $1.51, which does cover the dividend. Fair enough, but the cushion is thin, and one-time charges that repeat two years running deserve a skeptical eye.

Cash Flow Coverage Has Been Spotty Fiscal 2025 operating cash flow dropped 33.27% to $845.3 million while capex rose 21.24% to $310.9 million. Set capex and the $633.2 million dividend bill side by side, and together they exceeded the cash the business produced. Individual quarters were worse: in the quarter ending April 2025, operating cash flow of $56.4 million trailed dividends of $159.2 million.

The latest quarter improved. Operating cash flow rose 53.54% to $240.6 million against capex of $68.2 million and dividends of $161.0 million, which management credited to better inventory and working-capital management. One strong quarter helps. It does not yet prove a trend.

Balance Sheet Is Steady, but a Bill Is Coming Due Total debt was $2.855 billion at the end of July, essentially flat with $2.857 billion at fiscal 2025 year-end. The longer view is less comforting: debt stood at $250 million in fiscal 2019. Short-term debt jumped to $505.6 million from $6.6 million, signaling a maturity approaching, against cash of $839.6 million. Management called it “a sound financial position with ample liquidity and a conservative balance sheet.” That is true today, but refinancing or paying down that note competes with the dividend for the same cash.

Why a 60-Year Streak Cuts Both Ways On the August call, management said, “We remain committed to the dividend and are proud to have reached our 392nd consecutive quarterly payout.” CEO-elect John Ghingo added that “the dividend continues to be very important to us.”

That institutional pressure is real, and it brings down the odds of an outright near-term cut. It also explains the pattern: token raises, payouts held while earnings slide. A payout kept intact amid clear strain signals trouble rather than safety. The stress is visible: third-quarter revenue of $2.96B fell 2.4% and missed expectations, net income dropped 67.58%, and Ghingo said “the consumer environment right now really is not improving.” Leadership is also in transition, with an interim CEO and interim CFO on that call.

What Has to Go Right, and the One Number to Watch The path to safety exists. Foodservice posted its 12th consecutive quarter of organic sales growth, adjusted operating margin expanded to 9.0% from 8.4%, and management expects lower pork costs to flow through in future quarters, with a 53rd week in fiscal 2027 adding a boost. At 13x forward earnings, the market is partly pricing that recovery in. If the charges stop and cash flow holds at third-quarter levels, coverage repairs itself.

The verifiable test: when Hormel issues fiscal 2027 guidance, check whether the GAAP EPS range tops $1.17. If it does, the streak has breathing room. If it does not, Hormel faces a third straight year of paying more than it earns on a GAAP basis, and the risk rises sharply.

Dividend cuts rarely arrive alone; the stock usually falls with them. Hormel’s yield is fat because the stock has drop, and a 60-year streak can make a board stubborn right up to the point it cannot. The thesis rests on coverage.

Contact [email protected] for any questions or corrections.

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic therapy Phase 3 Viti-Up-1 and Viti-Up-2 studies show that among patients continuing RINVOQ, the proportions who achieved facial (F-VASI 75) and total body (T-VASI 50) repigmentation continued to increase through week 76 Findings from a phototherapy substudy show numerically higher responses with RINVOQ in combination with narrowband ultraviolet B (NB-UVB) phototherapy than with RINVOQ alone Data are being shared in a late-breaking oral presentation at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week 76.

Presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, data also include week-28 findings from a phototherapy substudy, in which treatment groups receiving RINVOQ plus whole-body narrowband ultraviolet B (NB-UVB) phototherapy showed numerically higher repigmentation responses than groups receiving RINVOQ alone.

"Vitiligo is a chronic, unpredictable disease that can affect skin across the body, underscoring the need for systemic treatment options that go beyond addressing individual areas," said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie. "These late-breaking data support that RINVOQ can provide meaningful long-term repigmentation for patients with vitiligo and provide an early foundation for further research into its combination with NB-UVB phototherapy."

Continued Repigmentation with RINVOQ Through 76 Weeks

Following the 48-week placebo-controlled period (Period A) in the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies, patients either entered an open-label extension (OLE) and received RINVOQ 15 mg once daily or entered a phototherapy substudy.

In patients who continued on RINVOQ 15 mg once daily in the OLE, proportions of patients achieving F-VASI 75 and T-VASI 50 continued to increase from week 48 through week 76. Results for F-VASI 75 and T-VASI 50 in both studies are shown in the tables below.

Viti-Up-1 & Viti-Up-2 Observed-Case Analyses

Viti-Up-1

Viti-Up-2

RINVOQ 15 mg
once daily at Week 48

(N=130)

Continued
RINVOQ 15 mg
once daily at Week 76

(N=127)

RINVOQ 15 mg
once daily at Week 48

 (N=145)

Continued
RINVOQ 15 mg
once daily at Week 76

(N=137)

F-VASI 75*          

33.1 %

55.1 %

27.6 %

47.4 %

T-VASI 50*

29.2 %

42.5 %

26.2 %

40.1 %

*F-VASI 75 = ≥75% reduction from baseline in Facial Vitiligo Area Scoring Index; T-VASI 50 = ≥50% reduction from baseline in Total Vitiligo Area Scoring Index

Findings With RINVOQ and NB-UVB Phototherapy

Following completion of Period A in Viti-Up-1 or Viti-Up-2, 84 adults who failed to achieve T-VASI 90 at week 48 and met additional eligibility criteria were re-randomized to receive RINVOQ 15 mg once daily alone or in combination with whole-body NB-UVB phototherapy twice weekly for 28 weeks.

All groups showed improvement in facial and total body repigmentation from baseline, with numerically higher response rates observed in the RINVOQ + NB-UVB phototherapy combination groups than in the RINVOQ monotherapy groups. Detailed F-VASI 75 and T-VASI 50 results are shown in the table below.

Efficacy at Week 28 (NRI*)

Viti-Up-1/2 Period A Treatment (Tx): Placebo

Phototherapy Substudy Tx:     

     RINVOQ     
(N=15)

     RINVOQ + NB-UVB     
(N=15)

F-VASI 75

40.0 %

46.7 %

T-VASI 50

20.0 %

33.3 %

Viti-Up-1/2 Period A Tx: RINVOQ

Phototherapy Substudy Tx:

RINVOQ
(N=27)

RINVOQ + NB-UVB
(N=27)

F-VASI 75

37.0 %

59.3 %

T-VASI 50

33.3 %

63.0 %

*NRI = Non-responder Imputation

"These findings are important for physicians treating people with vitiligo because they extend our understanding of repigmentation with continued RINVOQ treatment and provide the first data on combining NB-UVB with an approved systemic JAK inhibitor," said Julien Seneschal, M.D., Ph.D., professor of dermatology at the National Reference Center for Rare Skin Diseases, University of Bordeaux, France. "This research opens an important path for further investigation into how combination approaches could evolve to support patient care in non-segmental vitiligo."

Safety results for week 76 in Viti-Up-1 and Viti-Up-2 and for week 28 in the phototherapy substudy were consistent with the known safety profile of upadacitinib and with the profile observed during the 48-week Period A; no new safety signals were reported.

RINVOQ is the first and only systemic medication approved in the European Union for the treatment of adult and adolescent patients 12 years and older with NSV who are candidates for systemic therapy. The approval was based on results from the Phase 3 Viti-Up clinical program at week 48 versus placebo. The use of RINVOQ in non-segmental vitiligo is under regulatory review by the U.S. FDA.

About Viti-Up Clinical Trials 
Viti-Up (upadacitinib M19-044) consists of two ongoing replicate Phase 3 studies (Viti-Up-1 and Viti-Up-2) conducted under a single protocol, with independent randomization, investigative sites, data collection, analysis and reporting for each study. The trials evaluate the efficacy, safety and tolerability of upadacitinib in adult and adolescent patients (ages 12 and older) with non-segmental vitiligo (NSV) who are candidates for systemic therapy. In Period A of both studies, participants were randomized in a 2:1 ratio to receive either upadacitinib 15 mg once daily or placebo for 48 weeks. Participants who completed Period A were eligible to enter Period B, an 112-week open-label extension in which all patients, including those initially randomized to placebo, received upadacitinib 15-mg once daily; together, Periods A and B span 160 weeks. The two studies randomized 614 participants with NSV across 90 sites worldwide. Following completion of Period A in Viti-Up-1 or Viti-Up-2, 84 adults who failed to achieve T-VASI 90 at week 48 and met additional eligibility criteria were re-randomized to receive RINVOQ 15 mg once daily alone or in combination with whole-body NB-UVB phototherapy twice weekly for 28 weeks.

More information on these trials can be found at www.clinicaltrials.gov (NCT06118411).

About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1,2 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK 1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.1

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.

EU Indications and Important Safety Information about RINVOQ® (upadacitinib)1

Indications

Rheumatoid arthritis

RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis

RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Polyarticular juvenile idiopathic arthritis

RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA)

RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)

RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Giant cell arteritis

RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Atopic dermatitis

RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Alopecia areata

RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Vitiligo

RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis

RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease

RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:
- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy)

Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.

Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.

Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.

Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.

Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.

Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.

Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.

Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.

Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids. Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.

Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.

Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.

Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.

Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.

Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.

Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.

Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.

Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.

Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.

Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.

The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.

The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in paediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.

The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.

The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.

The most common serious adverse reactions were serious infections.

The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.

RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.

This is not a complete summary of all safety information.

See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

RINVOQ. Summary of product characteristics. AbbVie; 2026. Pipeline. AbbVie. 2026. Accessed September 8, 2026. https://www.abbvie.com/our-science/pipeline.html ALL-RNQD-260137

SOURCE AbbVie

Only a handful of companies have benefited more from the current artificial intelligence (AI) boom than Broadcom (AVGO -0.76%). Shares of the semiconductor giant are up 330% in the past three years, and Broadcom now sits as the world's ninth-most valuable company, with a market capitalization of $1.68 trillion (as of Sept. 28).

Broadcom has made plenty of millionaires through the years, but after its current run-up, has that ship sailed? If you have time on your side, I don't believe so.

Image source: Getty Images.

The math behind reaching $1 million from scratch Whether a stock is a millionaire maker depends largely on two things: how much you have to invest and how long you have to invest. If you have $500,000 to invest at once, reaching $1 million is much easier than if you needed $25,000 to grow 40-fold. The same goes for time. If you're trying to go from scratch to $1 million in a decade, you'll need much higher returns than someone with a 20-year horizon.

Investors are more likely to have time than a six-figure lump sum, so for our example, we'll assume a 20-year horizon. Here are different investment amounts and average annual return combinations that it would take to reach a million if you're starting from scratch:

Annual Investment (Monthly)Average Annual Returns$3,000 ($250)24.8%$6,000 ($500)19.1%$9,000 ($750)15.7%$12,000 ($1,000)13.3%$18,000 ($1,500)9.8% Data source: Table by author.

If you can invest $750 to $1,500 in Broadcom monthly, I see it as a millionaire maker. If you're starting from scratch and trying with just $250 monthly, it's a bit more far-fetched to happen in 20 years.

Premium Feature

Moneyball Superscore

90/100

Today's Change

(

-0.76

%) $

-2.68

Current Price

$

348.51

Riding a high, but built to last Broadcom's recent success is mostly due to its role in the AI ecosystem, supplying custom AI chips and networking equipment. In the third quarter (Q3), semiconductor revenue from AI jumped 221% year over year to $16.7 billion. In Q4, it expects it to jump 236% year over year to $21.7 billion. This continues an impressive run, with Broadcom's revenue and net income up 218% and 271%, respectively, over the past three years.

AVGO Revenue (Quarterly) data by YCharts

The current AI boom has Broadcom in a great place, but if you're investing with seven figures in mind, the business needs to be built to last. In Broadcom's case, it has done a good job building a hardware and software ecosystem that keeps business steady beyond the current hype.

AI aside, Broadcom's chips and wireless parts are used in everything from smartphones to broadband equipment to smart TVs. Right now, it has high customer concentration, with AI hyperscalers (companies that own major data centers) spending hundreds of billions to build out their data centers, but Broadcom's business is a huge part of the overall tech infrastructure.

Trading at 30 times its projected earnings over the next 12 months, Broadcom's stock is expensive. It's much cheaper than the 41 it traded at in June but still expensive enough that investors should be aware the stock could be vulnerable to a pullback. Still, if you're in it for the long haul, this shouldn't deter you.

 News Highlights:

HP OmniBook 5 combines vibrant OLED visuals, rich audio, and AI-enhanced capabilities to help consumers create, connect and be entertained wherever they goHP ProBook 4 equips growing businesses with AI-ready performance and portability to stay productive wherever work happens PALO ALTO, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Today, HP Inc. (NYSE: HPQ) announced the new HP OmniBook 5, a premium consumer Windows laptop designed for people who want more from their everyday device: more screen, more battery life, more connectivity and more freedom to create, connect and be entertained without compromise.

“Today's consumers expect technology that fits naturally into their lives – beautifully designed, easy to use, and powerful enough to support everything from collaboration and content creation to entertainment and everyday productivity,” said Samuel Chang, Senior Vice President and Division President, Consumer Personal Systems at HP Inc. “The new HP OmniBook 5 delivers exactly that, bringing together premium design and immersive experiences with a colorful OLED display in an incredibly portable package for work, study, and entertainment.”

Premium Experiences, Made Accessible
Consumers increasingly expect a PC that helps them stay productive, connected, and entertained without adding complexity to their lives. Whether streaming content, attending class, creating, collaborating, or staying connected with friends and family, they want premium experiences that fit their lifestyles, their budgets, and help prepare for what comes next. The HP OmniBook 5 was designed to deliver exactly that: bringing together thoughtful design, immersive entertainment, and everyday practicality in one accessible device.

Designed for students, young professionals and modern multitaskers, the device delivers the experiences people value most, from immersive entertainment to seamless connectivity, in a device built to fit naturally into everyday life:

Empowers productivity and creativity with AI-ready performance: Powered by up to an Intel® Core™ 7 processori with integrated NPU capabilitiesii, the HP OmniBook 5 helps users stay productive, communicate effectively and take advantage of the latest AI-ready experiences across work, school and personal projects.Adapts to life on the move with up to 42 hours of VPB (Local Video Playback) battery lifeiii and effortless mobility: Combining an ultra-thin 11.77 mm profile, lightweight 1.16 kg design, flexible 180° hinge, dual full-function USB-C®iv ports and HP's compact 65W USB Mini GaN chargerv, the HP OmniBook 5 is built to move effortlessly from campus to café, commute to couch and everywhere in between.Delivers rich entertainment experiences: Featuring up to a 2.5K OLEDvi touch display, 100% DCI-P3 color coverage, up to 620 nits brightnessvii, HP Eye Ease technology and up to a 90% screen-to-body ratio, the HP OmniBook 5 delivers vivid visuals and immersive entertainment wherever users go.Enhances seamless collaboration and connection: An FHD IR camera with Windows Hello facial recognition, dual microphones, Poly Studio-tuned audioviii and DTS:X Ultra help users show up clearly and confidently for classes, calls and everyday conversations.Expresses individuality through thoughtful design: Available in Smoke Silver, Starlit Blue, Peony Pink and Soft Honeydew, the HP OmniBook 5 combines a premium aluminum chassis, tone-on-tone keyboard and refined design details that help consumers choose a device that reflects their personal style. Premium Design, Built for Growing Businesses
HP is also bringing premium design and AI-ready performance to growing businesses with the HP ProBook 4. Purpose-built for SMBs and mobile professionals, the device delivers the design, mobility and performance growing businesses need without compromising on durability or value.

As HP’s thinnest business notebook,ix the HP ProBook 4 pairs a sleek 12mm thinx aluminum design with real portability, starting at just 2.6 lbs.,xi so it travels light without feeling delicate. The device comes in three finishes – Eclipse Gray, Atmospheric Blue, and Mist Silver – with a 14-inch 2.8K OLED displayxii bringing work to life with rich 100% DCI-P3 color and fluid 120Hz motion.

Powered by up to an Intel® Core™ 7 processori with up to 17 TOPS NPU AI accelerationxiii, up to 32 GB of memory and up to 1TB of storage, the HP ProBook 4keeps everyday productivity and AI-enhanced work moving. A 70Whr battery with HP Fast Charge,xiv along with MIL-STD durability,xv helps professionals work confidently.

Pricing and Availabilityxvi

The HP OmniBook 5 14 AI PC is expected to be available on HP.com and Best Buy in October for a starting price of $699.99.The HP ProBook 4 G2iS 14 AI PC is expected to be available on HP.com in November. Pricing will be announced closer to availability. About HP
HP Inc. (NYSE: HPQ) is a global technology leader and creator of solutions that enable people to bring their ideas to life and connect to the things that matter most. Operating in more than 170 countries, HP delivers a wide range of innovative and sustainable devices, services, and subscriptions for personal computing, printing, 3D printing, hybrid work, gaming, and more. For more information, please visit http://www.hp.com.

i Multi-core is designed to improve performance of certain software products. Not all customers or software applications will necessarily benefit from use of this technology. Performance and clock frequency will vary depending on application workload and your hardware and software configurations. Intel's numbering is not a measurement of higher performance. Models with Intel® Core™ 7 processors planned to be available mid-October 2026.
ii Features and software that require a NPU may require may require software purchase, subscription or enablement by a software or platform provider, and third-party software may have specific configuration or compatibility requirements. Potential NPU inferencing performance varies by use, configuration, and other factors.
iii Battery life tested by HP using continuous FHD video playback, 1080p (1920x1080) resolution, 200 nits brightness, system audio level as image default, player audio level at 100%, played full-screen from local storage, headphone attached or through speaker (if no audio jack port), wireless on but not connected. Actual battery life will vary depending on configuration and maximum capacity will naturally decrease with time and usage.
iv Actual throughput may vary. USB Type-C® and USB-C® are trademarks of USB Implementers Forum. DisplayPort™ and the DisplayPort™ logo are trademarks owned by the Video Electronics Standards Association (VESA®) in the United States and other countries.
v Performance and compatibility may vary by device. Subject to change without notice. Compared to previous generation HP power adapters.
vi Features may require software or other third-party applications to provide the described functionality. Internet service required and not included.
vii All performance specifications represent the typical specifications provided by HP's component manufacturers; actual performance may vary either higher or lower. 2K OLED version with up to 300 nits brightness available at launch. 2.5K OLED version with up to 620 nits brightness planned to be available March 2027.
viii Features may require software or other third-party applications to provide the described functionality. Internet service required and not included.
ix Based on HP’s internal analysis of HP business notebook PCs with preinstalled encryption, authentication, malware protection and BIOS-level protection, passing MIL-STD testing, USB-C docking including power delivery, clamshell form factor, Intel U series or AMD Ryzen Pro processors, HDMI, and at least 2 USB 3.1 Gen 1 ports, optional WWAN in HP’s current commercial portfolio as of September 26. Claim based on the lowest maximum published z-height of the device. Actual dimensions may vary by configuration and manufacturing tolerances.
x Based on HP internal analysis of product specifications, including thickness comparisons among HP commercial notebook PCs available as of 08/03/2026. Dimensions are typical. Actual dimensions may vary by +/- 0.5 mm, and height may vary by configuration. Maximum height does not include rubber feet.
xi Actual weight will vary by configuration.
xii All performance specifications represent the typical specifications provided by HP's component manufacturers; actual performance may vary either higher or lower.
xiii Features and software that require an NPU may require software purchase, subscription or enablement by a software or platform provider, and third-party software may have specific configuration or compatibility requirements. Potential NPU inferencing performance varies by use, configuration, and other factors.
xiv Recharges your battery up to 50% within 45 minutes when the system is off or in standby mode. Power adapter minimum of 65 watts required for battery capacities 56Whr or less. Power adapter minimum of 100 watts required for battery capacities greater than 56Whr and less than 83Whr. Power adapter minimum of 120 watts required for battery capacities greater than 83Whr and less than 100Whr. After charging has reached 50% capacity, charging will return to normal. Charging time may vary +/-10% due to System tolerance.
xv MIL STD 810 testing is not intended to demonstrate fitness for U.S. Department of Defense contract requirements or for military use. Test results are not a guarantee of future performance under these test conditions. Any accidental damage requires an optional HP Accidental Damage Protection Care Pack.
xvi Pricing and availability subject to change without notice.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/6cc6624d-02b2-4cd7-8f82-b10d366e3c7c
https://www.globenewswire.com/NewsRoom/AttachmentNg/a91d96ae-e54c-49e6-8fd7-e63d5f2cf13b
https://www.globenewswire.com/NewsRoom/AttachmentNg/9a0c5ddc-2a6f-44da-abb7-6a9a712cf234

Key Takeaways CVX is expanding its Venezuelan footprint with more than $7 billion in planned investment over five years.E became operator of Junin-5, a 35-billion-barrel heavy-oil field targeting 400,000 barrels per day by 2030.TTE and HAL are renewing Venezuelan activity through energy cooperation and development agreements. Venezuela’s oil and gas industry is attracting renewed interest from international energy companies, creating a potentially important investment theme for the global energy sector. Fresh agreements involving major producers and oilfield service companies point to increasing efforts to develop the country’s enormous hydrocarbon resources.

The renewed focus on Venezuela comes as global oil markets face continued supply uncertainty. Crude oil remained above $90 per barrel on Thursday as investors weighed recovering Middle East supplies against ongoing U.S.-Iran negotiations. Uncertainty surrounding the Strait of Hormuz and OPEC+’s decision to maintain November output quotas could increase the strategic importance of Venezuela’s large oil resource base.

Several companies with Venezuelan exposure have delivered strong share price gains over the past year. Eni S.p.A. (E - Free Report) shares have advanced 55.4%, while TotalEnergies SE (TTE - Free Report) , Halliburton Company (HAL - Free Report) and Chevron Corporation (CVX - Free Report) have gained 43.3%, 29.3% and 31.5%, respectively.

How Energy Stocks Have Performed Over the Past Year
Image Source: Zacks Investment Research

The gains highlight the strong recent performance of these energy stocks, although their future performance will depend on company-specific operating results, oil prices and the execution of Venezuelan projects.

The emerging Venezuela opportunity is centered on four themes: higher investment in Venezuelan oil assets, production growth, development of heavy-oil resources and rising demand for oilfield services. For investors, these trends could create different forms of exposure across the energy value chain, from upstream production to drilling and field-development services.

International Investment Could Accelerate Venezuela’s Oil DevelopmentVenezuela holds a massive resource base, particularly in the Orinoco Belt, where much of the crude is heavy or extra-heavy oil. Developing these resources requires substantial capital, specialized technology, infrastructure and long-term field-development plans.

Recent agreements indicate that international companies are increasing their involvement. Greater international participation could increase spending on drilling, reservoir evaluation, production infrastructure and enhanced oil recovery. This could benefit both producers and oilfield service companies as Venezuela attempts to translate its large resource base into higher commercial production.

Eni: Junín-5 Provides a Large-Scale Growth OpportunityEni provides significant upstream angle through its Junín-5 development. Eni and PDVSA signed a 25-year hydrocarbon participation contract on Sept. 2, 2026, under which Eni became the exclusive operator of the Junín-5 area. The heavy-oil field contains 35 billion barrels of certified oil in place and currently produces approximately 12,000 barrels per day.  

Eni and PDVSA plan to invest approximately $1.5 billion annually in the project. Reuters reported that production is expected to reach around 400,000 barrels per day by 2030.

The project could therefore become an important source of future production growth for Eni. Its scale also illustrates the capital and technical expertise required to develop Venezuela’s heavy-oil resources.

Eni already has an established Venezuelan presence through assets including the Perla gas field and Corocoro oil field. This existing operating experience could support its role in additional Venezuelan development projects. Eni sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

TotalEnergies: Potential Return to Venezuelan OilTotalEnergies represents a different form of exposure because its latest Venezuelan initiative remains at an earlier stage. TotalEnergies and PDVSA signed a memorandum of understanding (MOU) on Sept. 19, 2026, establishing a framework for energy cooperation in Venezuela. Details regarding the scope and value of the agreement have not been disclosed, making it premature to quantify the potential production or financial contribution.

For investors, the key factor will be whether the MOU develops into specific projects and capital commitments. At this stage, the agreement signals renewed engagement rather than a defined production program. TotalEnergies carries a Zacks Rank #2 (Buy).

Chevron: Direct Exposure to Venezuelan Production GrowthChevron offers direct exposure to Venezuela’s potential production expansion. On Sept. 2, 2026, Chevron announced updated agreements covering its Venezuelan joint ventures and additional acreage in the Orinoco Belt. The agreements underpin plans to invest more than $7 billion over the next five years and more than double production to approximately 600,000 barrels per day compared with 2026 levels. Chevron also reported that production from its three Venezuelan joint ventures increased 15% through the second quarter of 2026.

The company’s long operating history in Venezuela and existing infrastructure provide an established platform for additional development. Higher production could increase upstream volumes and strengthen Chevron’s long-term production portfolio. Chevron currently carries a Zacks Rank #3 (Hold).

Halliburton: Rising Activity Could Support Oilfield ServicesHalliburton provides exposure through the oilfield services side of Venezuela’s potential revival. It announced MOUs with Eneva and WESCA on Sept. 21, 2026, to support energy development opportunities in Venezuela. Under the WESCA agreement, Halliburton will support field evaluation and development planning, while its agreement with Eneva is intended to identify and pursue additional development opportunities.

This provides Halliburton with potential exposure to increased drilling, reservoir evaluation and development activity. Unlike Chevron and Eni, whose opportunities are directly linked to production growth, Halliburton’s potential benefit depends more on the level of capital spending and field-development activity generated by Venezuela’s producers. HAL carries a Zacks Rank #3.

ConclusionVenezuela’s renewed appeal among international energy companies is creating an emerging investment theme across the oil and gas value chain. Higher capital spending and development activity could support production growth while creating additional demand for specialized oilfield services.

CVX provides direct exposure through its expanding Venezuelan production portfolio, while E has a major development opportunity through Junín-5. TTE offers potential exposure to a renewed Venezuelan presence, while HAL could benefit from higher field-development and service activity.

For investors, the key factor to watch is the conversion of agreements and investment plans into actual projects, production growth and sustained industry spending. Venezuela’s large resource base creates significant potential, but the financial impact on individual companies will depend on project execution, capital requirements, oil prices, infrastructure development and the evolution of the country’s operating environment.

 | Source: Applied Materials, Inc.

Besi joins Applied's EPIC Center as an Innovation Partner, extending a collaboration that began in 2020 with the companies' joint Hybrid Bonding Center of Excellence in SingaporeExpanded collaboration targets next-generation 3D IC scaling, logic and memory integration, and photonics applications supporting AI infrastructure build-outPartnership expands beyond die-to-wafer hybrid bonding to new hybrid bonding platforms, scaling of thermo-compression bonding (TCB), and new die-on-wafer, die-on-die and die-on-panel architectures SANTA CLARA, Calif. and DUIVEN, The Netherlands, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Applied Materials, Inc. (Nasdaq: AMAT) and BE Semiconductor Industries N.V. (Besi) (Euronext Amsterdam: BESI) today announced an expansion of their longstanding strategic partnership, with Besi joining Applied's EPIC Center as an Innovation Partner. The collaboration builds on the companies’ joint development program launched in 2020 and extends co-innovation beyond hybrid bonding into new interconnect architectures and applications supporting the semiconductor industry's AI-driven scaling roadmap.

As the AI infrastructure build-out drives demand for higher-density, higher-bandwidth chip-to-chip and chip-to-package interconnects, the expanded partnership is intended to give mutual customers earlier access to co-optimized process and assembly solutions spanning the full advanced packaging flow – from wafer-level hybrid bonding through panel-scale integration.

In 2020, Applied and Besi established a joint Center of Excellence at Applied's Advanced Packaging Development Center in Singapore, combining Applied's process expertise in etch, planarization, deposition, wafer cleaning, metrology, inspection and particle defect control with Besi's die placement, interconnect and assembly technology. That collaboration resulted in Kinex™, the industry’s first integrated die-to-wafer hybrid bonding system.

“Besi has been a trusted partner since we began co-developing next-generation hybrid bonding solutions,” said Gary Dickerson, President and CEO of Applied Materials. “With Besi joining EPIC as an Innovation Partner, we’re extending that collaboration across the interconnect technologies our customers need to scale AI systems. Bringing this work into Applied's EPIC Center gives both companies earlier visibility into where the roadmap is headed and lets us co-optimize the full packaging flow.”

“Our center of excellence with Applied in Singapore has been foundational to Besi's hybrid bonding roadmap,” said Richard Blickman, CEO and Chairman of the Board of Management of Besi. “Joining Applied's EPIC Center as an Innovation Partner is a natural next step, giving us a seat alongside the leading logic, memory and systems companies as we advance TCB scaling, die-on-panel integration and the interconnect technologies that will define the next generation of AI and photonics systems”

As an Innovation Partner, Besi engineers will work alongside Applied's teams at the EPIC Center to accelerate joint development across a broader set of interconnect and integration technologies. While advanced packaging was historically treated as a back-end assembly step, technologies such as hybrid bonding and panel-level integration now depend on the same materials engineering disciplines that define front-end wafer fabrication.

“Advanced packaging is no longer a back-end assembly step – it is a materials engineering challenge that demands the same precision and cleanliness as front-end wafer fabrication,” said Dr. Prabu Raja, President of the Semiconductor Products Group at Applied Materials. “Developing these technologies together with Besi engineers in a front-end R&D environment like the EPIC Center will allow us to treat them as one connected flow rather than a series of isolated steps. That gives our mutual customers earlier access to co-optimized solutions and a faster path from development to high-volume manufacturing.”

The expanded scope of collaboration will focus on next-generation 3D IC scaling and logic and memory integration for AI compute and memory architectures, with expected R&D programs to include:

New platforms for die-to-wafer hybrid bonding, building on the companies' existing Singapore Center of ExcellenceScaling of thermo-compression bonding (TCB) and its surrounding process ecosystemNew die-on-wafer, die-on-die and die-on-panel integration platformsPhotonics-enabled interconnect applications supporting co-packaged optics and AI system scaling Applied’s new, $5 billion* EPIC (Equipment and Process Innovation and Commercialization) Center in Silicon Valley represents the largest-ever U.S. investment in advanced semiconductor equipment and process technology R&D. The center, which will be operationally ready this year, is designed from the ground up to dramatically reduce the time it takes to commercialize breakthrough technologies from early-stage research to full-scale manufacturing.

*Capital spending is expected to scale over time to approximately $5 billion as customer projects commence.

About Applied Materials
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions that are at the foundation of virtually every new semiconductor and advanced display in the world. The technology we create is essential to advancing AI and accelerating the commercialization of next-generation chips. At Applied, we push the boundaries of science and engineering to deliver material innovation that changes the world. Learn more at www.appliedmaterials.com.

Applied Materials Forward-Looking Statements
This press release contains forward-looking statements, including those regarding Applied's investment and growth strategies, the development of new materials and technologies, industry outlook and technology requirements, the plans and expectations for the EPIC Center, and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the demand for semiconductors and customers' technology requirements; the ability to develop new and innovative technologies; the ability to obtain and protect intellectual property rights in key technologies; the ability to achieve the objectives of the EPIC Center; and other risks and uncertainties described in Applied's filings with the Securities and Exchange Commission, including Applied's most recent Forms 10-K, 10-Q and 8-K. All forward-looking statements are based on management's current estimates, projections and assumptions, and Applied assumes no obligation to update them.

About Besi
Besi is a leading manufacturer of assembly equipment supplying a broad portfolio of advanced packaging solutions to the semiconductor and electronics industries. We offer customers high levels of accuracy, reliability and throughput at a lower cost of ownership with a principal focus on wafer level and substrate assembly solutions. Customers are primarily leading semiconductor manufacturers, foundries, assembly subcontractors and electronics and industrial companies. Besi’s ordinary shares are listed on Euronext Amsterdam (symbol: BESI). Its Level 1 ADRs are listed on the OTC markets (symbol: BESIY) and its headquarters are located in Duiven, the Netherlands. For more information, please visit our website at
www.besi.com.

Besi Forward-Looking Statements
This press release contains statements about management's future expectations, plans and prospects of our business that constitute forward-looking statements, which are found in various places throughout the press release, including, but not limited to, statements relating to expectations of orders, net sales, product shipments, expenses, timing of purchases of assembly equipment by customers, gross margins, operating results and capital expenditures. The use of words such as “anticipate”, “estimate”, “expect”, “can”, “intend”, “believes”, “may”, “plan”, “predict”, “project”, “forecast”, “will”, “would”, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The financial guidance set forth under the heading “Outlook” contains such forward-looking statements. While these forward-looking statements represent our judgments and expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from those contained in forward-looking statements, including any inability to maintain continued demand for our products; failure of anticipated orders to materialize or postponement or cancellation of orders, generally without charges; the volatility in the demand for semiconductors and our products and services; failure to develop new and enhanced products and introduce them at competitive price levels; failure to adequately manage costs and expenses in line with revenue; loss of significant customers, including through industry consolidation or the emergence of industry alliances; lengthening of the sales cycle; acts of terrorism and violence; disruption or failure of our information technology systems; consolidation activity and industry alliances in the semiconductor industry that may result in further increased customer concentration, inability to forecast demand and inventory levels for our products; the integrity of product pricing and protection of our intellectual property in foreign jurisdictions; risks, such as changes in trade regulations, conflict minerals regulations, currency fluctuations, political instability and war, associated with substantial foreign customers, suppliers and foreign manufacturing operations, particularly to the extent occurring in the Asia Pacific region where we have a substantial portion of our production facilities; potential instability in foreign capital markets; the risk of failure to successfully manage our diverse operations; any inability to attract and retain skilled personnel, including as a result of restrictions on immigration, travel or the availability of visas for skilled technology workers; and the other risks detailed in the Risk Management section of our Annual Report. We expressly disclaim any obligation to update or alter these forward-looking statements for revisions or changes whether as a result of new information, future events or otherwise after the date of this release.

In addition, the United States and other countries have recently levied tariffs and taxes on certain goods and could significantly increase or impose new tariffs on a broad array of goods. They have imposed, and may continue to impose, new trade restrictions and export regulations. Increased or new tariffs and additional taxes, including any retaliatory measures, trade restrictions and export regulations, could negatively impact end-user demand and customer investment in semiconductor assembly equipment, increase Besi’s supply chain complexity and manufacturing costs, decrease margins, reduce the competitiveness of our products or restrict our ability to sell products, provide services or purchase necessary equipment and supplies. Any or all of the foregoing factors could have a material and adverse effect on our business, results of operations or financial condition. In addition, investors should consider those additional risk factors set forth in Besi's annual report for the year ended December 31, 2025 and other key factors that could adversely affect our businesses and financial performance contained in our filings and reports, including our statutory consolidated statements. We expressly disclaim any obligation to update or alter our forward-looking statements whether as a result of new information, future events or otherwise.

Contacts:

Applied Materials
Ricky Gradwohl (editorial/media) 408.235.4676
Mike Sullivan (financial community) 408.986.7977

Besi
Richard W. Blickman, President & CEO 
Andrea Kopp-Battaglia, Senior Vice President Finance  
Claudia Vissers, Executive Secretary/IR coordinator 
Edmond Franco, VP Corporate Development/US IR coordinator 
Tel. (31) 26 319 4500, [email protected]    

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against DICK'S Sporting Goods, Inc. ("Dick's" or the "Company") (NYSE: DKS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Dick's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 3, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Dick's securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. 

[Click here for information about joining the class action]

On September 8, 2025, Dick's announced the completion of its acquisition of Foot Locker, Inc. ("Foot Locker"), a prominent footwear and apparel retailer, for approximately $2.5 billion in cash and stock.

On August 25, 2026, before the market opened, Dick's issued a press release announcing its financial results for the second quarter of 2026.  Specifically, the Company reported adjusted earnings per share of $3.53 per share, which fell short of analysts' estimates of $3.76 per share.  Notably, Dick's also disclosed that Foot Locker generated revenue of only $1.73 billion, significantly below analysts' expectations of $1.81 billion.  The Company also reduced its full-year 2026 consolidated net sales guidance to a range between $21.9 billion to $22.2 billion (down from $22.1 billion to $22.4 billion).  Dick's further revealed that it expected Foot Locker's proforma comparable sales to yield a range of negative 2.0% to 0.0% for the year – a sharp deterioration from Dick's prior forecast of 1.5% to 3% growth for Foot Locker.

In the press release, Executive Chairman Edward Stack conceded that "[a]s the quarter progressed, conditions across portions of the athletic footwear and apparel marketplace became increasingly promotional, and we took action to remain competitively priced."  Stack further explained that this environment had a more "significant impact" on Foot Locker due to its "greater exposure to legacy footwear silhouettes and greater dependence on footwear launch and retro product."  Stack also noted that "[n]ot only were there fewer launches in the second quarter, but those launches performed below both industry and our expectations."

Following these disclosures, Dick's stock price fell $55.02 per share, or approximately 30%, to close at $124.31 per share on August 25, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

GREENWICH, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- XPO (NYSE: XPO), a leading provider of freight transportation in North America, today announced the opening of two new service centers in Mesa, Arizona, and Cameron, Missouri. The facilities expand XPO’s capacity to meet growing freight demand in the Phoenix and Kansas City metropolitan areas.

Matt Carroll, president of XPO’s West Division, said, “These new service centers deepen our presence in two critical freight markets and reflect our strategic approach to investing in our network. We’ve added capacity where our customers need it most, positioning us to support their growth while delivering the world-class service they count on.”

The 51,000-square-foot Mesa facility has 86 dock doors and a team of more than 100 employees. Located in one of the nation’s largest and fastest-growing metropolitan areas, it complements XPO’s existing Phoenix service center, adding capacity to meet increasing freight demand fueled by industrial investment and cross-border trade with Mexico.

The 13,000-square-foot Cameron service center has 32 dock doors and a team of more than 30 employees. Located at the intersection of two major highways, I-35 and U.S. 36, it enables more efficient freight movement along key north-south and east-west freight corridors in the Midwest.

XPO has opened nearly 35 new service centers across the country since 2021, expanding its network dock door capacity by 15%. Construction at the Mesa and Cameron sites was completed this summer, and their openings bring XPO’s North American network to 300 service centers, which provide direct service to 99% of U.S. ZIP codes and cross-border service to and from Canada and Mexico.

About XPO
XPO, Inc. (NYSE: XPO) is a leader in asset-based less-than-truckload (LTL) freight transportation in North America. The company’s customer-focused organization efficiently moves 16 billion pounds of freight per year, enabled by its proprietary technology. XPO serves 55,000 customers with 586 locations and 38,000 employees in North America and Europe, and is headquartered in Greenwich, Conn., USA. Visit xpo.com for more information, and connect with XPO on LinkedIn, Facebook, X, Instagram and YouTube.

Investor Contact
Brian Scasserra
+1-617-607-6429
[email protected]

Media Contact
Cole Horton
+1-203-609-6004
[email protected]

Meta's new shopping agent rattled online travel stocks almost equally, but Booking Holdings and Expedia chose opposite responses to the threat. One strategy leaves a company dangerously exposed if Meta decides to cut out the middleman entirely.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Meta Platforms (NASDAQ:META | META Price Prediction) launched Muse, a shopping agent that reached 560,000 daily active users within 11 days.

Truist then cut price targets on Booking Holdings (NASDAQ:BKNG) and Expedia Group (NASDAQ:EXPE) on the same day, citing Muse.

Both online travel agencies (OTAs) kept their ratings. Booking stayed at Buy with its target cut from $242 to $216, and Expedia stayed at Hold with its target cut from $309 to $288. The two companies responded to Muse differently, and Booking’s approach likely holds up better.

Expedia Joined Muse While Booking Kept Its Direct Channel Expedia partnered with Muse and is integrated for travel booking there. That suits a company whose B2B revenue, which powers other brands’ travel sites, grew 23% last quarter.

Booking stayed out. Its consumer direct mix held in the mid-60% range for four quarters, and large language models send “significantly below one percent” of its room nights.

Partnering risks teaching Meta how travelers shop, which could help it bypass Expedia later, and declining risks missing agent-first travelers, a smaller cost while that traffic stays tiny.

Independent Hotels Keep Booking Essential to AI Agents The same firm estimated that only about 10% of Booking’s room nights come from the top global hotel brands. Big chains run loyalty programs and booking systems an AI agent can plug into directly, but independent hotels lack that technology, so an agent seeking their rooms still needs Booking. Booking also processes payment on approximately 73% of gross bookings, which keeps it inside the transaction.

Both stocks have already absorbed similar damage.

Booking fell 17.98% over the past month, and Expedia fell 16.95%, nearly identical damage. Booking’s 25-to-1 stock split effective April 2, 2026 explains why its $162.91 shares look small beside Expedia’s $263.36. On forward earnings, Booking trades at 13 times and Expedia at 11 times.

Target Cuts Came With an Admission of Uncertainty The firm warned that Meta poses “greater downside risks to OTAs given the company’s strong consumer position,” but admitted the “extent to which Muse or other AI agents will affect OTA bookings share remains highly uncertain.”

Retail shows the same split: Amazon (NASDAQ:AMZN) blocked Muse, while Walmart (NASDAQ:WMT), Wayfair (NYSE:W) and Sephora joined as launch partners. Meta’s chief executive said Meta will profit from a small transaction fee, a toll that would likely come out of travel sellers’ margins.

Booking Looks Better Positioned to Withstand Muse Booking looks better placed of the two. Revenue of $7.35 billion beat estimates, Transformation Program savings now target about $650 million by the end of 2027, and its hotel base sits further from Muse.

Expedia posted 14% revenue growth and raised guidance, but its partnership strategy leaves it more exposed if Meta’s fee pressures partner economics.

My view changes if Booking reports large language model traffic climbing well above 1% of room nights. Pair that with a direct mix sliding below the mid-60s, and Booking would be paying for customers it once owned.

Contact [email protected] for any questions or corrections.

Key Takeaways Neogen's Food Safety revenues rose 3.1%, with core growth reaching 5.8% in fiscal 2026's fourth quarter.Petrifilm remains a key asset as Neogen brings manufacturing in-house and expands its product platform.Neogen plans to boost fiscal 2027 R&D spending 50%, targeting pathogen detection and sanitation platforms. Neogen (NEOG - Free Report) shares have shown impressive momentum so far this year, surging 83%. The stock has outpaced the industry’s 21.6% fall and the S&P 500 composite’s 11.7% rise.  

Carrying a Zacks Rank #2 (Buy) at present, the company’s Food Safety strength and solutions-based selling strategy are supporting growth momentum and portfolio expansion. Neogen is expanding its product and manufacturing capabilities following the 3M Food Safety combination, with Petrifilm playing a key role. It also continues to expand its product pipeline with new launches and differentiated technologies.

Neogen develops, manufactures and markets a diverse line of products and services dedicated to food and animal safety. The company’s Food Safety segment markets diagnostic solutions, test kits, culture media and complementary products used to detect foodborne pathogens, natural toxins, allergens and sanitation concerns. Its Animal Safety portfolio includes life sciences products, veterinary instruments and disposables, animal care products, pest control solutions and genomics services. In March 2026, Neogen agreed to sell its Genomics business to Zoetis for $160 million, subject to regulatory approvals and customary closing conditions.

Factors Supporting NEOG’s Price RallyThe rally in the company’s share price can be linked to the continued momentum in Neogen’s Food Safety segment, its central growth engine, which is supported by a broad portfolio spanning indicator testing, culture media, pathogen detection and sanitation. In the fourth quarter of fiscal 2026, segment revenues jumped 3.1% year over year, while core growth reached 5.8%, the highest quarterly rate since fiscal 2023. Indicator Testing and Culture Media revenues rose 9.5%, while Bacterial and General Sanitation increased 9.9%.

Image Source: Zacks Investment Research

The company is also shifting toward global solutions-based selling, with resources focused on strategic accounts, disciplined segmentation and higher-return geographies. Management expects this model to deepen portfolio penetration and improve customer engagement. 

Neogen’s 2022 combination with 3M’s Food Safety business continues to expand its product breadth and manufacturing capabilities, with Petrifilm remaining a key strategic asset. The company is bringing Petrifilm manufacturing in-house at its Lansing facility. The new manufacturing platform is also designed to support broader innovation, including additional Petrifilm SKUs and expansion into pharmaceuticals, nutraceuticals and consumer products.

Neogen continues to expand its product pipeline across Food and Animal Safety while directing more resources toward differentiated technologies. Recent launches include Neogen MPNTray, the Listeria Right Now molecular detection assay, Igenity BCHF and MDA2 Quantitative Salmonella. Listeria Right Now received AOAC Performance Tested Methods certification in fiscal 2026, supporting broader commercial use of the enrichment-free environmental monitoring test.

Strategically, the company is advancing a three-part transformation centered on commercial execution, innovation and operational efficiency. The commercial program is moving from local product-led selling toward a global solutions-based model, with sales resources being realigned around priority countries, customer segments and strategic accounts. Neogen expects fiscal 2027 research and development (R&D) spending to rise about 50% from fiscal 2026, focused on Petrifilm, informatics, technology licensing and next-generation platforms in pathogen detection and general sanitation.

What Ails NEOG?Historically, Neogen has faced intense competition resulting from the development of new technologies by the company’s competitors, which could affect the marketability and profitability of its products. It also remains materially exposed to foreign currency fluctuations, with international sales accounting for 51.2% of fiscal 2026 revenues.

A Glance at NEOG’s EstimatesThe Zacks Consensus Estimate for NEOG’s fiscal 2027 earnings per share (EPS) is expected to drop 3.1% from 2026 to 31 cents. In the past 60 days, the estimate has risen 1 cent. Meanwhile, fiscal 2028 EPS is projected to grow 17.2% to 36 cents.

The company’s fiscal 2027 revenues are projected to rise 1.5% to $883.2 million, while fiscal 2028 revenues are expected to fall 4.2% to $846.5 million.

Other Key PicksSome other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Phibro Animal Health (PAHC - Free Report) and Globus Medical (GMED - Free Report) .

Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 29.1% compared with the industry’s 8.2% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Phibro Animal Health, sporting a Zacks Rank #1, has an earnings yield of 10.2% compared with the industry’s 2.5% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 18.4%. PAHC shares have fallen 8.2% against the industry’s 27.7% decline over the past year.

Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 29% compared with the industry’s 8.3% growth over the past year.

Vancouver, British Columbia--(Newsfile Corp. - October 1, 2026) - Canagold Resources Ltd. (TSX: CCM) (OTCQB: CRCUF) (FSE: CANA) ("Canagold" or the "Company") announces assay results from five drill holes completed as part of its recently concluded 14-hole resource infill and expansion drilling program targeting the high-grade antimony zone at its 100%-owned New Polaris Gold Project, located in northwestern British Columbia ("BC"), approximately 100 kilometres (km) south of Atlin, BC, and 60 km northeast of Juneau, Alaska.

The drill program was designed to further define and expand the high-grade antimony mineralization identified at New Polaris, while also evaluating its potential to contribute to the Project's gold resources. Highlights of the antimony and gold mineralization intersected in the five drill holes are summarized below, with complete drill-hole results and locations provided in Table 1 and Figure 1.

Highlights

3.83% Sb and 19.38 Au grams per tonne (g/t) Au over 13.20 meters (m) from 451.75 m down hole in hole NP26-01 including 1.21 m grading 30.46% Sb and 49.10 g/t Au. 3.90% Sb and 14.97 g/t Au over 6.06 m from 477.44 m down hole in hole NP26-02 including 0.83 m grading 24.68 % Sb and 29.0 g/t Au.3.30% Sb and 15.08 g/t Au over 3.91 m from 451.19 m down hole in hole NP26-03 including 1.81 m grading 6.99% Sb 26.3 g/t Au."These results are highly significant for New Polaris, representing the highest Sb grades over the greatest widths encountered at the Project to date," stated Catalin Kilofliski, Canagold's CEO. "Importantly, they suggest that the scale of the Sb mineralization may be substantially larger than we originally understood. This creates an opportunity to significantly expand the high-grade Sb and gold resources and, importantly, positions Sb as having the potential to become a meaningful contributor to the overall value and economics of New Polaris."

Table 1

Drill holeFrom (m)To (m)Interval (m)Sb (%)Au (g/t)NP26-01451.75464.9513.203.8319.38Including455.00456.211.2130.4649.10NP26-02477.44483.506.063.9014.97Including478.22479.050.8324.6829.00NP26-02487.50490.352.850.1117.10NP26-03451.19455.103.913.3015.08Including451.19453.001.816.9926.3NP26-05488.83493.564.731.505.76Including490.83491.560.738.5012.80*The New Polaris resource is contained within an Updated Resource report which was prepared by Moose Mountain Technical Services in the format prescribed by NI43-101 Standards of Disclosure for Mineral Projects, and filed on Sedar June 30,2023.

Additional Drilling Highlights

Hole IDInterval
* (m)Sb %Au (gpt)From (m)NP26-022.85 m0.1017.1gpt487.5 mNP26-06B8.22 m0.0116.47gpt472.6 mDrill Hole Details

Hole IDUTM E
NAD83UTM N
NAD83Elev
(m)Azi
(deg)Dip
(deg) Depth
(m)NP26-0157933065070773090.68 -83.18479NP26-02579330650707730101.23-83.73515NP26-03579322650711032103.19-83.7480NP26-05579330650707730111.48-78.04516NP26-06B57933065070773079.71-86.25522Drill intercepts shown are core length as insufficient drilling and modelling has taken place to determine the true dip and strike orientation of the veins being intercepted.

Figure 1

The drilling program has been completed with 7,277m being drilled in 14 holes. The drilling has intersected multiple zones of mineralization in this area.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11878/316852_aeea4c1f842e3ab4_001full.jpg

Drill Core Sampling and Quality Assurance – Quality Control Program

Drill core is geologically logged to identify the gold mineralized zones that are allocated unique sample number tickets and marked for cutting using a purpose-built diamond blade rock saw. Half core samples are collected in labelled bags and the other half remains in the original core box stored on site. Quality control (QC) samples including certified reference material standards, blanks and duplicates are inserted into the sample sequence at intervals of one in ten on a rotating basis to monitor laboratory performance and provide quality assurance (QA) of the assay results. Several sample bags are transported together in rice bags with unique numbered security tags attached and labelled with Company and lab contact information to ensure sample security and chain of custody during shipment to the lab.

Diamond drill core samples were prepared at MSA Labs' Preparation Laboratory in Terrace, BC and assayed at MSA Labs' Geochemical Laboratory in Langley, BC. Analytical accuracy and precision are monitored by the submission of blanks, certified standards and duplicate samples inserted at regular intervals into the sample stream by Canagold personnel. MSA Laboratories quality system complies with the requirements for the International Standards ISO 17025 and ISO 9001. MSA Lab is independent of the Company.

Qualified Person

In accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects, Garry Biles, P.Eng, President & COO is the Qualified Person for the Company and has prepared, validated, and approved the technical and scientific content of this news release. The Company strictly adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting activities on its projects.

About Canagold

Canagold Resources Ltd. is an advanced development company dedicated to advancing the New Polaris Project through feasibility, permitting, and production stages. Additionally, Canagold aims to expand its asset base by acquiring advanced projects, positioning itself as a leading project developer. With a team of technical experts, the Company is poised to unlock substantial value for its shareholders.

"Catalin Kilofliski"

Catalin Kilofliski
Chief Executive Officer

Website: www.canagoldresources.com

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/316852

Source: Canagold Resources Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Marvell just posted record revenue and raised guidance, yet its stock sits nearly 20% off its highs while AI sentiment drags it lower. Three upcoming catalysts could determine whether this gap closes or widens.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Marvell Technology (NASDAQ:MRVL | MRVL Price Prediction) trades at $264.21, and pullbacks have tested the stock’s momentum. A sector-wide slide in AI hardware names this week, after a 214.95% one-year run, makes this the moment to settle on a view.

Marvell designs custom AI chips, optical interconnects and Ethernet switches for hyperscale data centers. Data Center revenue hit $2.17 billion last quarter, up 46% year over year and now 79% of sales. Record total revenue of $2.739 billion exceeded estimates. Management also raised guidance and expanded its custom silicon deal with Google parent Alphabet (NASDAQ:GOOGL), which includes a warrant for up to 7% of Marvell’s shares tied to revenue milestones.

Accelerating Growth Drives a Wave of Estimate Hikes Third-quarter revenue guidance of $3.15 billion implies more than 50% growth at the midpoint, with Data Center up roughly 75%. Fiscal 2027 revenue is now expected near $12 billion, and fiscal 2028 growth was raised to approximately 50%. Management expects the custom business to more than double in fiscal 2028.

Analysts have raised estimates. The fiscal 2028 EPS consensus rose to $6.7609 from $6.2425 a month ago, with 33 upward revisions against one cut. A PEG ratio of 1.387 suggests growth justifies the premium, and the upcoming Investor Day should measure the Google opportunity beyond fiscal 2028.

Premium Multiple Leaves Little Room for Stumbles Shares trade at 83x trailing earnings with a beta of 2.253, so any wobble in AI spending hits hard. A handful of hyperscalers drive revenue, and customers could build more silicon in-house. Third-quarter non-GAAP gross margin guidance of 57.5% to 58.5% reflects mix pressure from the custom ramp.

The $120 billion cumulative Google figure depends on milestones, and the warrant means dilution if those milestones are hit. Stock-based compensation rose to $207.6 million in the first quarter from $142.1 million a year earlier, alongside $4.963 billion of long-term debt.

Investor Day Detail Could Decide the Next Move Recent beats were narrow, with revenue just 1.20% above consensus. The stock still sits 19.9% below its $329.8 52-week high, a sign that enthusiasm has already cooled once. Investors will look for fiscal 2029 custom targets and confirmation that the business delivers $1.05 to $1.15 in third-quarter EPS while communications revenue dips.

Wall Street Still Sees Upside After a Triple-Digit Run The consensus target of $290.97 implies 10.1% upside from $264.21 across 44 analysts. Targets are one data point, and they can lag fast-moving stocks.

Strong Buy: 8 Buy: 31 Hold: 5 Sell: 0 Marvell is up 211.36% year to date versus 11.81% for the S&P 500. Over the past month it gained 24.83% while the index slipped 0.6%. The forward P/E stands at 62x. Runs like this are what we reverse-engineered in a free playbook on spotting the next Nvidia-style winner early.

Custom Silicon Scaling Sets Up Three Key Catalysts Marvell trades at $264.21.

The path higher runs through three catalysts: Investor Day details on fiscal 2029 custom revenue, a third-quarter report that confirms growth above 50%, and operating margin reaching the 38% to 40% target range in the fourth quarter. Each one helps earnings catch up to the multiple.

Volatility comes with the stock. Selloffs driven by sector sentiment, like this week’s slide in AI names, have pressured shares of a business whose estimates keep moving up.

The thesis breaks if hyperscalers cut capital spending, custom ramps slip, or margins fall below guidance. Keep an eye on gross margin and Data Center growth each quarter.

Rising estimates and a expanding custom pipeline keep fundamentals at the center of the Marvell story as sentiment-driven dips come and go.

Contact [email protected] for any questions or corrections.

It cost bitcoin miners an average of about $75,500 in cash to produce one coin in the second quarter. Meanwhile, bitcoin itself ended June at $58,400, less than half its October 2025 record high. That gap pushed publicly traded miners below cash breakeven as a group, according to CoinShares’ Q2 2026 Bitcoin Mining Report by Luke Nolan. Cash cost covers day-to-day spending such as power, staff and interest, but not equipment wear.

Key Takeaways: Listed miners spent about $75,500 in cash per bitcoin last quarter, well above the coin’s June close. Grid delays and state restrictions have turned existing power connections into a scarce asset for AI data centers. WGMI broadened its strategy in August to include data centers, AI chipmakers and power producers alongside miners. See more: Why Bitcoin Miners Stopped Tracking Bitcoin’s Price

Rather than wait out the slump, many miners are renting their power sites to AI and high-performance computing (HPC) customers. The report estimates AI computing earns about $1.5 million in yearly profit per megawatt of power, versus $0.5 million for mining.

The shift is changing what investors own when they buy mining stocks. Companies with signed AI or HPC contracts traded at an average 12.9 times expected sales for the next year, the report found. Miners without such contracts, by contrast, averaged 3.7 times. In other words, the market values those miners at less than a third as much per dollar of sales.

Power is now the scarce resource. At least 151 restrictions on data center development remain in force across the U.S., the report showed. New York, for example, enacted the first statewide pause on permits for large data centers in July.

Power projects totaling about 2,600 gigawatts are also waiting to connect to the U.S. grid, the report said. That backlog is roughly double the grid’s installed capacity.

As a result, prices have climbed for sites that already have power. A $3.5 billion deal for three leased Northern Virginia AI facilities worked out to about $27 million per megawatt, the report noted. By comparison, the market values some listed miners’ powered but unleased sites at less than $3 million per megawatt.

Bitcoin Miners Pay to Stop Mining Some companies are paying to exit. Core Scientific, Inc. (CORZ) paid $41.9 million to cancel an order for next-generation mining chips, according to the report. Those chips are the most efficient mining hardware produced to date.

Mining brings in about 13% of the company’s revenue as it converts sites for AI use, the report said. Its remaining machines run at a loss, only to use up power it has already agreed to buy.

Keel Infrastructure Corp. (KEEL), formerly Bitfarms, stopped mining on June 29, according to the report. That makes it the first listed miner headed for zero mining revenue, starting in the third quarter.

At IREN Ltd. (IREN), AI cloud revenue of $70.5 million topped mining revenue of $66.7 million for the first time, per the report.

Most of the sector’s contracted AI revenue has not arrived yet, though. More than $100 billion in disclosed contracts supports only about $1.1 billion in yearly AI and HPC revenue, according to the report.

Several of these miners anchor the CoinShares Bitcoin Mining and Digital Power ETF (WGMI). Eight of the report’s 12 companies ranked among its top 10 holdings as of September 29, CoinShares data show.

On August 18, the fund broadened its strategy to include data center operators, AI chipmakers, power producers and HPC firms. The actively managed ETF does not, however, hold bitcoin directly, CoinShares said.

WGMI held $291.5 million in assets as of September 28 and charges a 0.75% expense ratio, according to CoinShares.

Cipher Digital Inc. (CIFR), the fund’s largest holding, will likely exit mining by the end of 2027, the report said. In the first half, it sold $123.4 million of bitcoin at a $47.7 million loss to help fund buildings for data center tenants.

For more news, information, and strategy, visit the CoinShares Crypto ETF Hub.

Premier Graphene Inc. and Affiliate HGI Industrial Technologies S.A.P.I. de C.V. Receive Payment for Mexican Military Purchase Order

Key Highlights: Payment received: Premier and HGI completed delivery of 98 military waist belts for SEDENA and received payment.

Manufacturing expansion: HGI and Nova Graphene signed a joint venture agreement for a Mexican plant; financing is pending, and the facility is not operational.

Conditions remain: Revenue recognition awaits review, and Premier’s planned U.S. procurement activities depend on obtaining required certification.

PR Audio:

Mexico City, Mexico, October 1, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Premier Graphene Inc. (OTC: BIEI) (the “Company” or “Premier”), together with its affiliate and strategic partner HGI Industrial Technologies S.A.P.I. de C.V. (“HGI”), today announced that payment was received on the first purchase order fulfilled by HGI and Premier for Mexico’s Secretaría de la Defensa Nacional (SEDENA).

Premier Graphene (OTC: BIEI) and affiliate HGI received payment for their first fulfilled purchase order for Mexico’s defense ministry, SEDENA, covering 98 military waist belts The purchase order, documented under Remisión No. 001 dated May 8, 2026, involved the manufacture and delivery of 98 military waist belts (fajillas), consisting of:

• 35 units — Fajilla with TE-3A belt

• 35 units — Fajilla with NC belt

• 28 units — Fajilla with TE-3 belt

The fulfillment of these 3 separate contracts, while profitable, more significantly, demonstrated to the Mexican government, the professionalism of Premier and its team, coupled with the capacity to competently and expeditiously, deliver quality, compliant products and fulfill all responsibilities, paving the way to more significant and far more profitable contracts.

The accounting treatment, classification, and timing of any related revenue remains subject to determination by the Company’s management and independent auditors, in accordance with U.S. generally accepted accounting principles (GAAP).

HGI Industrial Technologies continues expanding its manufacturing and commercial operations in Mexico, while Premier Graphene Inc. is developing its position as a publicly traded company with exposure to advanced materials, graphene-related technologies, and strategic manufacturing opportunities.

“This payment marks another important milestone for HGI and Premier Graphene,” said Pedro A. Méndez, President of Premier Graphene Inc. and HGI Industrial Technologies S.A.P.I. de C.V. “Our focus has always been on turning opportunities into actual purchase orders, delivering the products, and ultimately converting those orders into collected revenue. Receiving payment is an important part of that process.”

The Companies expect to continue building upon their existing commercial relationships while pursuing additional opportunities in Mexico and international markets.

As part of their broader strategic development, HGI Industrial Technologies S.A.P.I. de C.V. and Nova Graphene Inc. are moving forward under a signed Joint Venture agreement focused on establishing a dedicated manufacturing plant in Mexico. The Joint Venture agreement was signed approximately one month ago, and the parties are currently awaiting financing to proceed with the planned facility. The facility is intended to support the production of advanced graphene-related and protective products for Mexico and international markets, subject to securing adequate financing. The planned plant is not yet operational.

Nova Graphene has tested and NIJ-certified ballistic plate products at Level III-A and Level IV, along with additional military applications and advanced materials. The planned manufacturing platform in Mexico is intended to build upon these existing technologies and capabilities and, if financed and established, could support production and commercial opportunities in Mexico, the United States, Europe, and Middle Eastern markets, subject to applicable financing, regulatory, and certification requirements.

Premier Graphene Inc. expects to pursue U.S. industrial and military procurement opportunities, including next-generation graphene-enhanced protective vests and other graphene-enhanced military products, as part of its broader North American market strategy. These activities are subject to Premier Graphene Inc. obtaining at least one type of required certification which has not yet been obtained.  Despite the probability of receiving all such certifications, there can be no assurance that all will be received and thus all such opportunities will be realized.

About HGI Industrial Technologies S.A.P.I. de C.V.

HGI Industrial Technologies S.A.P.I. de C.V. is a Mexican technology and industrial solutions company focused on advanced materials, specialized manufacturing, graphene technologies, and related products serving commercial and strategic markets. HGI is a strategic partner and affiliate of Premier Graphene Inc.

About Premier Graphene Inc. (OTC: BIEI)

Premier Graphene Inc. (OTC: BIEI) is a publicly traded company focused on the commercialization and development of advanced materials, graphene technologies, industrial solutions, manufacturing, and related technologies through strategic partnerships and commercial initiatives.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the companies’ future business activities, anticipated commercial opportunities, planned manufacturing operations and the proposed manufacturing plant in Mexico, market development, and future revenue and profitability. Words such as “anticipates,” “expects,” “believes,” “plans,” “intends,” “may,” “will,” “could,” “should,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations, estimates, and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to, the timing and recognition of revenue; the companies’ ability to perform under, and collect payment on, purchase orders and contracts; changes in customer and governmental purchaser requirements; the receipt, timing, scope, and maintenance of regulatory certifications and authorizations, including export and import approvals; the availability of capital and financing for the planned manufacturing plant and other initiatives; competitive and market conditions; and other risks beyond the companies’ control. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and to review the companies’ public filings and disclosures. Premier Graphene Inc. and HGI Industrial Technologies S.A.P.I. de C.V. undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Media Contact:

Pedro Mendez, President
Premier Graphene Inc. / HGI Industrial Technologies S.A.P.I. de C.V.
Website: https://premiergrapheneinc.com/
Email: [email protected]
Investor Relations: [email protected]

Source: Premier Graphene Inc.

The latest news and updates relating to $BIEI are available at the company’s newsroom: https://tinyurl.com/bieinewsroom

$BIEI RSS: https://prismmediawire.com/category/biei/feed/

PMW Newsroom Feed: https://prismmediawire.com/feed/

Follow @prism_mediawire>

Conagra Brands, Inc. (CAG) Q1 2027 Earnings Call September 29, 2026 8:00 PM EDT

Company Participants

Matthew Neisius - Senior Director of Investor Relations
John Brase - CEO, President & Director
David Marberger - Executive VP & CFO

Presentation

Matthew Neisius
Senior Director of Investor Relations

Good morning. Thank you for listening to our prepared remarks for the Conagra Brands First Quarter Fiscal 2027 Earnings. At 9:30 a.m. Eastern this morning, we will hold a separate live question-and-answer session on today's results, which you can access via webcast on our Investor Relations website. Our press release, presentation materials and a transcript of these prepared remarks are also available there. In our presentation this morning, John Brase, our CEO, and Dave Marberger, our CFO, will be making some forward-looking statements.

And while we're making those statements in good faith based on current information, we don't have any guarantee about the results we'll achieve. Descriptions of our risk factors are included in our filings with the SEC. We'll also be discussing some non-GAAP financial measures. GAAP to non-GAAP reconciliations and information on our comparability items are in our earnings release and presentation materials in the Investor Relations section of our website. I'll now turn the call over to John.

John Brase
CEO, President & Director

Good morning, everyone, and thank you for joining us. When we last spoke in July, I outlined the priorities that I believe will strengthen Conagra and position the business for sustainable growth. After spending the quarter working closely with our teams and engaging across the organization, I'm even more confident that we're focused on the right opportunities and taking the right actions. There are 3 points I'd like you to take away from today. First, we delivered a solid start to the fiscal year despite a challenging operating environment. Dave and I will get into the details here shortly. But

Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence

, /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in specimens from the landmark DYNAMIC colorectal cancer trial series. The study also validated the test’s analytical performance across 23 solid tumor types. Provided by Quest Diagnostics (NYSE: DGX), Haystack MRD is an ultrasensitive circulating tumor DNA (ctDNA) liquid biopsy test for identifying residual or recurrent disease in patients with solid tumor cancers. 

The study evaluated the clinical performance of the commercially available Haystack MRD test by retrospectively testing residual specimens from patients enrolled in the DYNAMIC and DYNAMIC-III trials, which evaluated the use of ctDNA-based MRD results (generated with an earlier version of the Haystack MRD technology) to guide chemotherapy decisions in stage II and III colorectal cancer. In this cohort, Haystack MRD results were highly associated with recurrence, demonstrating 100% sensitivity and 100% specificity at 3-year follow-up and 83.3% sensitivity and 100% specificity at 5-year follow-up. Haystack MRD also substantially outperformed carcinoembryonic antigen (CEA), a standard blood-based biomarker, detecting recurrence with 88.9% sensitivity versus 11.1% for CEA (median follow-up 60 months).

Scientists from Quest and Haystack Oncology conducted the study together with investigators from the two institutions that led the DYNAMIC trials: The Walter and Eliza Hall Institute of Medical Research and the Peter MacCallum Cancer Center in Melbourne, Australia.

"The DYNAMIC trial demonstrated the potential for ctDNA to guide more individualized treatment decisions in stage II colon cancer but realizing that potential depends on a highly sensitive assay that can reliably detect the extremely small amounts of tumor DNA that may remain after treatment, while maintaining high specificity," said Professor Jeanne Tie,* a medical oncologist at Peter MacCallum Cancer Centre and lead investigator for the DYNAMIC trial series. "This study helps bridge the gap between clinical research and real-world patient care."

In other key findings, Haystack MRD:

Demonstrated ultrasensitive detection of residual disease, with a 95% limit of detection (LoD95) of 0.063 mean ctDNA molecules per milliliter (mL) of plasma. Earlier validation established an LoD95 of 6 parts per million (PPM), a metric commonly reported for tumor-informed MRD assays1. Achieved sub-PPM detection of 0.8 PPM, and as low as 0.2 PPM in some samples, with no false positives in cancer-free controls using an investigational whole-genome version of the test. This whole-genome version is currently only available to clinical investigators and biopharma partners while the commercial test uses whole-exome sequencing. Established a limit of quantitation (LOQ) suitable for response monitoring of 0.25 mean ctDNA molecules per mL. Establishing the LOQ allows a change in a patient's ctDNA level between serial tests to be interpreted as a real change in tumor burden rather than assay variability. Demonstrated analytical performance across the complete testing process, starting from plasma collection and including cell free (cf) DNA extraction, rather than starting with already extracted cfDNA. As a result, analytical performance can be directly translated to clinical performance, versus assay validations that begin with extracted cfDNA and do not account for extraction variability.   "To our knowledge, this is the first time that the full ctDNA MRD testing process, starting from plasma collection and including cfDNA extraction, has been characterized for the limit of detection (at 95%) and quantitative analytical performance," said study co-author Dan Edelstein, Vice President and General Manager, Haystack Oncology. "The precise quantitative measurements demonstrated in this validation provide confidence that the Haystack MRD test accurately measures changes in ctDNA levels over time and can be used for serial ctDNA monitoring during and after treatment. With these insights, clinicians can understand the degree of change in ctDNA levels related to tumor biology in an individual patient, supporting earlier evaluation of treatment response and detection of molecular progression or recurrence." 

In addition, the study examined a real-world clinical cohort from an Early Experience program in which Haystack MRD detected ctDNA across 27 solid tumor types, including at ultra-low concentrations, with 42% of positive results below 0.5 mean ctDNA molecules/mL.

The new study adds to the growing body of evidence supporting the clinical value of Haystack MRD, following two studies published in The New England Journal of Medicine. Published in 2022, DYNAMIC was the first prospective, interventional study to demonstrate the clinical utility of ctDNA-based MRD testing to reduce the use of chemotherapy in stage II colon cancer without compromising recurrence-free survival. In 2025, a study on response to immunotherapy in mismatch repair-deficient cancers found that the Haystack MRD test was a "reliable liquid biopsy surrogate" that identified clinical complete response at a median of 1.4 months, compared with more than 6 months using imaging.

*Dr. Tie has served as an advisor and consultant for Haystack Oncology.

About Quest Diagnostics

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com

About Haystack Oncology

Haystack Oncology represents the culmination of over 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine. The company, a wholly owned subsidiary of Quest Diagnostics, developed Haystack MRD, a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual or recurrent disease with exceptional sensitivity and specificity. Haystack Oncology works with biopharmaceutical companies to accelerate and inform clinical development programs and advance important therapeutics to global markets, from early phase clinical development to companion diagnostics. Haystack MRD was developed and validated in a CLIA-certified laboratory and is available for commercial use as a lab-developed test (LDT) by Quest Diagnostics. The FDA granted Haystack MRD Dx Breakthrough Device Designation in 2025 for use in Stage II colorectal cancer. Haystack MRD is also available for clinical trials as an investigational device by Haystack Oncology in laboratories located in Baltimore, Maryland; Hamburg, Germany; and Helsinki, Finland. Haystack MRD is now authorized for patient access in all 50 U.S. states. www.haystackmrd.com

Prathapam R, Champion K, Blakely K, et al. Analytical validation of the Haystack MRD assay for the detection of extremely low ctDNA in solid tumor patients. Poster presented at: Association for Molecular Pathology 2024 Annual Meeting and Expo; November 19, 2024; Vancouver, BC, Canada. doi:10.1016/S1525-1578(24)00232-0 SOURCE Quest Diagnostics

Public Service Enterprise Group Incorporated (NYSE:PEG – Get Free Report) shares hit a new 52-week low on Tuesday. The company traded as low as $66.15 and last traded at $66.9710, with a volume of 69286 shares traded. The stock had previously closed at $66.73.

Analyst Ratings Changes A number of brokerages have commented on PEG. Citigroup cut their price target on shares of Public Service Enterprise Group from $91.00 to $84.00 and set a “neutral” rating for the company in a research note on Wednesday, August 5th. Morgan Stanley lowered their price objective on shares of Public Service Enterprise Group from $91.00 to $88.00 and set an “overweight” rating on the stock in a research note on Friday, September 18th. Wells Fargo & Company dropped their target price on shares of Public Service Enterprise Group from $91.00 to $89.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Weiss Ratings downgraded shares of Public Service Enterprise Group from a “buy (b-)” rating to a “hold (c)” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen upgraded Public Service Enterprise Group from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $89.23.

Check Out Our Latest Analysis on PEG

Public Service Enterprise Group Price Performance The company has a market capitalization of $33.59 billion, a P/E ratio of 16.76, a price-to-earnings-growth ratio of 2.55 and a beta of 0.50. The company’s 50-day moving average price is $73.48 and its two-hundred day moving average price is $77.84. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.88 and a quick ratio of 0.67. Public Service Enterprise Group (NYSE:PEG – Get Free Report) last posted its earnings results on Tuesday, August 4th. The utilities provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. Public Service Enterprise Group had a net margin of 16.04% and a return on equity of 12.42%. The company had revenue of $2.55 billion during the quarter, compared to analysts’ expectations of $2.66 billion. During the same quarter last year, the company posted $0.77 EPS. Public Service Enterprise Group’s quarterly revenue was down 8.9% compared to the same quarter last year. Public Service Enterprise Group has set its FY 2026 guidance at 4.280-4.400 EPS. As a group, sell-side analysts expect that Public Service Enterprise Group Incorporated will post 4.36 EPS for the current year.

Public Service Enterprise Group Announces Dividend The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a $0.67 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $2.68 annualized dividend and a dividend yield of 4.0%. Public Service Enterprise Group’s dividend payout ratio is presently 66.67%.

Insider Buying and Selling In related news, CEO Ralph LaRossa sold 2,083 shares of Public Service Enterprise Group stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $76.47, for a total transaction of $159,287.01. Following the completion of the sale, the chief executive officer directly owned 283,656 shares of the company’s stock, valued at approximately $21,691,174.32. This trade represents a 0.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Richard Thigpen sold 8,000 shares of Public Service Enterprise Group stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $74.56, for a total value of $596,480.00. Following the sale, the senior vice president directly owned 20,970 shares of the company’s stock, valued at approximately $1,563,523.20. The trade was a 27.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.19% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Public Service Enterprise Group Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in Public Service Enterprise Group during the second quarter worth about $4,366,570,000. State Street Corp raised its position in shares of Public Service Enterprise Group by 1.4% in the second quarter. State Street Corp now owns 29,481,434 shares of the utilities provider’s stock valued at $2,392,713,000 after buying an additional 399,191 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Public Service Enterprise Group in the second quarter valued at approximately $1,207,400,000. Legal & General Group Plc bought a new stake in shares of Public Service Enterprise Group in the second quarter valued at approximately $554,994,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Public Service Enterprise Group by 5.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,994,372 shares of the utilities provider’s stock valued at $401,048,000 after buying an additional 241,058 shares during the period. Institutional investors and hedge funds own 73.34% of the company’s stock.

(Get Free Report)

Public Service Enterprise Group Incorporated (NYSE: PEG) is an energy company headquartered in Newark, New Jersey. Founded in 1903, the company operates primarily through its regulated utility subsidiary, Public Service Electric and Gas Company (PSE&G), and its competitive energy businesses.

PSE&G is New Jersey’s largest electric and gas utility, providing electricity and natural gas delivery, transmission, distribution, and related customer services to residential, commercial, and industrial customers across the state.

Recommended Stories Five stocks we like better than Public Service Enterprise Group Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors? O’Reilly Automotive’s Stock Slump Hides a Stronger Business McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test Receive News & Ratings for Public Service Enterprise Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Public Service Enterprise Group and related companies with MarketBeat.com's FREE daily email newsletter.

Production deliveries begin in October with completion expected by the end of November as KULR expands its role in the U.S. defense drone supply chain

HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a developer of safe, high-power energy systems that enable physical AI across space, defense, drones, data centers, robotics, and other mission-critical applications, today announced that it has received more than $1 million in production purchase orders for high-performance battery systems supporting the U.S. Department of War’s (DoW) Drone Dominance Program.

Deliveries are scheduled to begin in October 2026, with KULR expecting to complete all shipments by the end of November 2026, providing near-term revenue visibility and demonstrating the Company’s ability to move defense programs into production.

The Drone Dominance Program is a $1.1 billion, multi-phase DoW initiative focused on accelerating the procurement and fielding of small unmanned aerial systems. KULR believes its position at the battery-system level creates an opportunity to support increasing production volumes as participating platforms advance through the program.

The production orders also represent an important validation of KULR’s investment in Forge 2, its new manufacturing facility in Houston, Texas, as the Company transitions customer programs from qualification into scaled production. Forge 2 increases KULR’s capacity to support defense drones and other autonomous platforms, positioning the Company as an important high-volume domestic supplier of battery systems designed to meet NDAA requirements as the first DoW compliance deadline approaches in 2027.

“These purchase orders mark another meaningful step in KULR’s expansion within the defense drone market,” said Michael Mo, Chief Executive Officer of KULR Technology Group. “Our focus is execution -- building and delivering advanced battery systems at the volumes our customers require. As U.S. drone production scales, successful execution positions KULR to support larger requirements and additional platform opportunities.”

Rising demand for KULR’s high-performance battery systems reflects accelerating U.S. defense investment in next-generation unmanned systems, where power, reliability, safety, and performance are mission-critical. KULR’s technology is engineered to meet these demanding requirements across advanced UAS platforms.

Safe Harbor Statement
This release contains certain forward-looking statements based on our current expectations, intentions and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, as may be amended or supplemented by other reports we file with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All such forward-looking statements that are provided by management in this release are based on information available at this time, and management expects that internal expectations may change over time. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Except as otherwise required by applicable law, we assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.

About KULR Technology Group, Inc.
KULR Technology Group, Inc. (NYSE American: KULR) is an energy-systems platform company that designs and manufactures safe, high-power battery solutions for physical AI and other mission-critical applications. Its KULR ONE® platform integrates advanced battery architecture, thermal management, safety engineering, battery management systems, and power electronics to serve space and defense, drones and electric aviation, AI data-center backup, robotics, and Energy-as-a-Service markets. Based in Webster, Texas, KULR is scaling domestic production to support the growing energy demands of physical AI and autonomous systems. Learn more at KULR.ai.

Find KULR: Website | X | Telegram | LinkedIn | Instagram | TikTok | Facebook

Investor Relations:
KULR Technology Group, Inc.
Email: [email protected]

Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report)’s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $15.48, but opened at $18.91. Summit Therapeutics shares last traded at $16.3970, with a volume of 10,558,930 shares traded.

Key Summit Therapeutics News Here are the key news stories impacting Summit Therapeutics this week:

Positive Sentiment: AstraZeneca’s investment validates Summit and provides substantial funding. AstraZeneca will invest $2 billion for an approximately 12% stake in Summit and collaborate on multiple clinical studies involving ivonescimab. The investment gives Summit additional resources to advance development while bringing validation from a major global pharmaceutical company. AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets Positive Sentiment: Analysts characterized the transaction as a “win-win.” UBS said the partnership could benefit both companies by supporting ivonescimab’s development and potentially broadening its commercial opportunity. The strategic collaboration also helped drive a sharp rally in Summit shares after the announcement. AstraZeneca’s $2 Billion Investment in Summit Therapeutics Seen as ‘Win-Win,’ UBS Says Positive Sentiment: The deal substantially exceeds Summit’s recent market valuation. Commentary noted that AstraZeneca agreed to a valuation that the public market had not been matching, suggesting potential upside if ivonescimab’s clinical results support the partnership’s expectations. Summit Shares Jump on $2B Strategic Investment From AstraZeneca Neutral Sentiment: Clinical execution remains the key near-term issue. Two clinical milestones expected in 2026 are likely to determine whether Summit’s valuation converges toward analyst targets or remains pressured. Positive trial data could further support the AstraZeneca deal, while disappointing results would weaken the investment thesis. AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets Negative Sentiment: The transaction does not eliminate biotechnology risk. Summit remains dependent on successful clinical development and regulatory progress for ivonescimab. The equity investment also introduces some dilution for existing shareholders, while the large valuation implied by AstraZeneca’s purchase could raise expectations ahead of the upcoming data readouts. Analysts Offer Insights on Healthcare Companies Analysts Set New Price Targets Several equities research analysts recently weighed in on SMMT shares. Stifel Nicolaus dropped their price target on Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, July 24th. Citigroup reiterated a “buy” rating and issued a $43.00 price objective (up from $40.00) on shares of Summit Therapeutics in a report on Friday, September 25th. Morgan Stanley lowered Summit Therapeutics to an “outperform” rating in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Summit Therapeutics in a research report on Tuesday, September 22nd. Finally, Leerink Partners upgraded shares of Summit Therapeutics from an “underperform” rating to a “market perform” rating and boosted their target price for the company from $12.00 to $13.00 in a report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Summit Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.45.

Check Out Our Latest Report on SMMT Summit Therapeutics Price Performance The stock’s 50 day simple moving average is $15.01 and its two-hundred day simple moving average is $16.34. The firm has a market cap of $13.49 billion, a P/E ratio of -15.10 and a beta of -1.24.

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). Equities research analysts anticipate that Summit Therapeutics PLC will post -1.2 earnings per share for the current year.

Institutional Investors Weigh In On Summit Therapeutics A number of institutional investors have recently modified their holdings of SMMT. Ball & Co Wealth Management Inc. bought a new position in shares of Summit Therapeutics during the first quarter valued at $28,000. Parallel Advisors LLC boosted its stake in Summit Therapeutics by 4,178.0% in the 1st quarter. Parallel Advisors LLC now owns 2,139 shares of the company’s stock worth $41,000 after purchasing an additional 2,089 shares in the last quarter. Fifth Third Bancorp grew its position in Summit Therapeutics by 24.4% during the 1st quarter. Fifth Third Bancorp now owns 3,732 shares of the company’s stock valued at $71,000 after purchasing an additional 732 shares during the last quarter. Osterweis Capital Management Inc. purchased a new stake in Summit Therapeutics during the 2nd quarter valued at about $73,000. Finally, Havemeyer Place LP bought a new stake in Summit Therapeutics during the 4th quarter valued at about $109,000. 4.61% of the stock is owned by hedge funds and other institutional investors.

Summit Therapeutics Company Profile (Get Free Report)

Summit Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition targeting PD-1 with anti-angiogenic activity targeting VEGF. Summit is evaluating ivonescimab in clinical studies for multiple solid tumors, including non-small cell lung cancer.

Summit obtained exclusive rights from Akeso, Inc to develop and commercialize ivonescimab in markets outside China, including the United States and other international territories.

Further Reading Five stocks we like better than Summit Therapeutics Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors? O’Reilly Automotive’s Stock Slump Hides a Stronger Business McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Scales quantum optimization to up to nearly 10,000 variables, a 10x increase over QCi's current 1,000-variable system, while delivering faster performance, production-ready reliability and scalable manufacturing First customer shipment of Dirac-3S upgrade expected in Q4 2026 , /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), a vertically integrated quantum systems company pioneering photonics and semiconductor manufacturing, today announced Dirac-3S, the next-generation of its Dirac-3 quantum optimization machine, marking a significant step toward commercial deployment of QCi's quantum optimization technology.

Dirac-3S advances the platform across three areas – Speed, Scale and Solutions – with faster performance, improved solution quality, increased computing capacity and a modular architecture designed to support customers as their requirements grow.  The first customer shipment of Dirac-3S is expected in November 2026.

Speed. Scale. Solutions.

Speed: Dirac-3S is engineered to efficiently solve increasingly complex optimization problems, with practical computation times demonstrated on problems involving up to 9,980 variables while consistently finding the optimal solution. This enables customers to tackle larger problems and explore more possibilities in less time.

Scale: Dirac-3S features a modular architecture designed to scale with customer requirements. The compact 5U base system can be extended with Expansion Modules to support larger and more complex optimization problems, with QCi demonstrating configurations supporting up to 9,980 variables with one Expansion Module. The architecture is designed to accommodate additional Expansion Modules, enabling customers to expand their system as their optimization needs grow. QCi has also advanced the Dirac-3S hardware architecture, manufacturing processes and supply chain to support increased production volumes, consistent product quality and broader commercial deployment. These improvements include enhanced error correction, component control and operational reliability.

Solutions: Dirac-3S is designed to address a broad range of real-world optimization problems on a single platform, through multiple optimization approaches including continuous, integer and higher-order optimization. QCi's latest error-correction techniques are designed to improve solution quality across applications in financial services, logistics and supply chains, manufacturing, energy, telecommunications, scientific research, and aerospace and defense.

The platform can be deployed on-premises or in the cloud and integrated into AI/ML pipelines, enabling organizations to incorporate quantum optimization into existing computational workflows.

"Dirac-3S takes our quantum optimization platform from demonstrating what is possible to delivering a system built for practical commercial use," said Yong Meng Sua, Chief Technology Officer of QCi. "We have increased performance and computing capacity, expanded the size and complexity of problems the system can address through a modular architecture, and advanced the hardware and manufacturing architecture needed to support broader deployment. This gives customers a flexible path to adopt quantum optimization and scale their computing capacity as their needs grow."

Building on the Dirac-3 Foundation

Dirac-3S builds on QCi's first-generation Dirac-3 quantum optimization machine, which has been used by academic researchers exploring quantum optimization algorithms and applications.

"Our experience with the first-generation Dirac-3 quantum optimization machine validated its potential as a powerful tool for solving meaningful optimization problems. QCi's continued innovation with the Dirac-3S, including its expanded computational capabilities, enables us to pursue significantly larger and more complex optimization challenges. We look forward to exploring new research directions and accelerating the development of practical, high-impact applications," said Professor Paul Griffin, Associate Professor, Singapore Management University.

QCi has published a new Technical Review evaluating Dirac-3S across synthetic, graph-based and industry-standard optimization benchmarks, including comparisons with Projected Gradient Descent and commercial classical solver Hexaly. On synthetic problems with known global optima ranging from 2,000 to 9,980 variables, Dirac-3S was the only evaluated solver to achieve the optimal solution across all tested instances, while solution times increased only modestly as problem size approached 9,980 variables. On industry-standard DIMACS maximum-clique benchmarks, Dirac-3S more frequently identified the highest-quality solutions than the other evaluated methods.

QCi has also published a survey paper demonstrating how NP-hard problems can be mapped to simplex formulations native to Dirac-3S, expanding its potential applications across continuous, discrete and combinatorial optimization. The Technical Review, along with the detailed benchmarking methodology and results is available in QCi's Dirac-3S Technical Reference at: https://quantumcomputinginc.com/learn/module/dirac-3s-technical-reference.

To learn more about the Dirac-3S, visit QCi's Dirac-3S webpage.

Quantum Computing Inc. (Nasdaq: QUBT) is a vertically integrated quantum systems company pioneering photonics and semiconductor manufacturing, and delivering accessible, scalable, and cost-effective quantum machines, photonics products, and advanced packaging. The Company provides foundry services for photonic chips and semiconductor manufacturing and offers a vertically integrated portfolio spanning photonics and electronic components, subsystems, and full-stack systems.

Designed to operate at room-temperature with low-power requirements, QCi's technologies enable practical deployment across high-growth markets, including high-performance computing, artificial intelligence, cybersecurity, aerospace and defense, and advanced sensing and imaging.

Headquartered in Hoboken, New Jersey, QCi also has operations in Arizona, California, Illinois, Indiana, Massachusetts, North Carolina and Virginia. By combining advanced materials, device engineering, and scalable manufacturing, QCi delivers integrated quantum, photonics, and semiconductor technologies, accelerating commercialization and real-world adoption.

Company Contacts:

Investor Relations
David Moskowtiz, Head of Investor Relations
[email protected]

Media & Communications
Karen Jeffers, Director, Marketing and Communications
[email protected]

Agency Contact:

IMS Investor Relations
John Nesbett/Zach Nevas
[email protected]

Forward-Looking Statements

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forecasts, generally identified by terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "enhance," "intends," "goal," "objective," "seek," "attempt," "aim to," or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of QCi and members of its management as well as the assumptions on which such statements are based.  Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including the timing of the first delivery of a Dirac-3S, the ability of the  Dirac-3S to solve larger and more complex problems than the first generation of Dirac-3, deliver higher quality solutions and faster performance, the functionality of the Dirac-3S modular design, and delivering improvements in the performance, system maturity and manufacturability, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward- looking statements to reflect changed conditions.

SOURCE Quantum Computing Inc.

Acquisition would provide NANO Nuclear with strategically valuable NRC-licensed fuel cycle assets and optionality to pursue domestic nuclear fuel cycle activities, independently or in collaboration with strategic partners

Upon completion of the transaction and transfer of the NRC license, NANO Nuclear would own one of ten NRC-licensed fuel cycle facilities in the United States

New York, New York--(Newsfile Corp. - October 1, 2026) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or the "Company"), an advanced nuclear energy and technology company developing microreactors, nuclear fuel cycle capabilities and nuclear transportation solutions, today announced that NANO Nuclear and its wholly owned subsidiary, HALEU Energy Fuel Inc., have entered into a definitive asset purchase agreement with Radnostix, Inc. (formerly International Isotopes Inc.) and its subsidiary International Isotopes Fluorine Products, Inc. to acquire strategic U.S. nuclear fuel processing assets, including a U.S. Nuclear Regulatory Commission ("NRC") license and related intellectual property and technical materials associated with a previously planned depleted uranium hexafluoride ("DUF6") deconversion and fluorine extraction facility in Lea County, New Mexico.

The proposed acquisition would provide NANO Nuclear with existing NRC-licensed fuel cycle assets and a substantial body of associated licensing and technical work. Upon completion of the transaction and transfer of the NRC license, NANO Nuclear would own one of ten NRC-licensed fuel cycle facilities in the United States. The acquisition is also subject to the satisfaction of future closing conditions.

Figure 1 - NANO Nuclear Energy Advances Vertical Integration Strategy by Signing Definitive Agreement to Acquire Strategic NRC-Licensed U.S. Nuclear Fuel Processing Assets - IIFP General Site Location, Proposed Facility Boundary, and Plant Throughput for the DUF₆ Deconversion Process.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11703/316891_ce00829e142b3b35_003full.jpg

By acquiring an existing NRC-licensed fuel cycle asset, NANO Nuclear is strategically positioned with the flexibility to pursue a depleted uranium hexafluoride ("DUF6) deconversion facility or additional fuel cycle processes through amendments to the existing NRC license, which NANO Nuclear believes could provide a significantly more efficient regulatory pathway than developing and licensing a comparable facility on a new site. The licensing, regulatory, engineering and technical foundation derived from the acquired assets could also inform and potentially streamline the development and licensing of similar fuel cycle capabilities at other locations. Together, these assets would provide NANO Nuclear with increased optionality to pursue domestic fuel cycle opportunities, either independently or in collaboration with other nuclear fuel processing companies.

If completed, the proposed acquisition would represent another important milestone in NANO Nuclear's long-term strategy to establish a vertically integrated advanced nuclear energy and fuel platform, extending its potential capabilities, whether internally or through strategic collaborations, across uranium conversion, enrichment, deconversion and transportation through reactor deployment.

Figure 2 - NANO Nuclear Energy Advances Vertical Integration Strategy by Signing Definitive Agreement to Acquire Strategic NRC-Licensed U.S. Nuclear Fuel Processing Assets

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11703/316891_ce00829e142b3b35_004full.jpg

Establishing a Strategic U.S. Nuclear Fuel Cycle Platform

The NRC license was originally issued to construct and operate a DUF6 deconversion and fluorine extraction facility in Lea County, New Mexico. The proposed acquisition also includes related patented technology, engineering and safety analyses, regulatory and permitting materials, equipment and historical project development records. The facility contemplated under the existing license was not previously constructed.

While the site is licensed by the NRC under 10 CFR Part 40, "Domestic Licensing of Source Material," the licensing basis was required by the NRC to meet applicable requirements of Subpart H of 10 CFR Part 70, "Domestic Licensing of Special Nuclear Material," in connection with a rulemaking framework previously contemplated by the NRC. NANO Nuclear expects the acquisition of an existing licensed fuel cycle facility developed to these requirements to facilitate a more streamlined regulatory pathway for adding certain additional fuel cycle processes requiring authorization under 10 CFR Part 70 through future license amendments if desired, subject in each case to applicable NRC review and approval.

Following closing and transfer of the NRC license, NANO Nuclear plans to continue its evaluation of several options in determining the optimal commercial and development pathway for the acquired assets, including potential deconversion and other fuel cycle activities, as well as opportunities to collaborate with potential strategic partners. No final investment decision has been made, and any future development remains subject to applicable technical, commercial, financing and regulatory considerations.

"This proposed acquisition is fundamentally about securing a strategically valuable position within the U.S. nuclear fuel cycle," said James Walker, Chief Executive Officer of NANO Nuclear Energy. "An existing NRC-licensed fuel cycle facility, supported by years of regulatory and technical development, provides us with a foundation we believe is extremely difficult to recreate from the ground up. It gives us multiple potential pathways to expand our domestic fuel cycle capabilities while preserving the flexibility to determine the development strategy that creates the greatest long-term value."

"Our objective is to build the capabilities necessary to support a more complete and resilient domestic nuclear energy industry," said Jay Yu, Founder and Chairman of NANO Nuclear Energy. "This transaction would establish another critical pillar of our vertically integrated nuclear fuel strategy, providing us with an important platform from which to pursue future fuel cycle opportunities, both independently and alongside strategic industry collaborators. I am very pleased with our continued business and commercial approach to creating long-term shareholder value in the nuclear energy sector."

Transaction Terms and Next Steps

Under the asset purchase agreement, the consideration being paid for the assets at closing is $9.5 million in cash and $4.0 million in NANO common stock, payable and issuable at closing in accordance with the agreement. Closing remains subject to NRC consent to the license transfer, other required approvals and consents (including from New Mexico officials), satisfactory site arrangements and other closing conditions. The parties currently expect closing in approximately 90 to 120 days, although the timing will depend on those approvals and conditions.

About NANO Nuclear Energy, Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.

Led by a world-class nuclear engineering team, NANO Nuclear's reactor products in development include the proprietary KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, the ZEUS™ system, a portable solid core battery reactor, and the space focused, portable LOKI MMR™ system, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear's developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS' initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface.

For more corporate information please visit: https://NanoNuclearEnergy.com/

Cautionary Note Regarding Forward-Looking Statements

This news release and statements of NANO Nuclear's management and collaborators in connection with this news release contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "explore," "plans", "aim," "goal," "believes", "potential", "future," "will", "should", "could", "would" or "may" or derivations of these words and other words of similar meaning about the future, although forward-looking statements could be denoted by other terms as well. In this press release, forward-looking statements include those relating to (i) the future anticipated closing of the asset purchase agreement with Radnostix described herein, which remains subject to significant conditions to closing, including NRC approval, and other conditions precedent and (ii) the anticipated potential benefits to NANO Nuclear of the assets to be acquired and its vertical integration strategy and other business plans. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to, risks associated with conditions to closing the asset purchase agreement, which may not be satisfied, including for reasons beyond NANO Nuclear's control, as well as the following: (i) risks related to our U.S. Department of Energy ("DOE"), U.S. Nuclear Regulatory Commission ("NRC"), Canadian Nuclear Safety Commission ("CNSC") or related state or other U.S. or non-U.S nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) risks related to our ability to obtain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the U.S. Department of Energy, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/316891

Source: NANO Nuclear Energy Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us